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Left ventricular hypertrophy (LVH) confers a high cardiovascular risk independent of 
blood pressure. It is prevalent in hypertensive patients even when the blood pressure 
is controlled, and LVH regression has prognostic benefit. Residual risk remains in well 
controlled hypertension and therefore novel non-blood pressure lowering therapies 
are required to regress LVH with the aim of improving cardiovascular morbidity and 
mortality.  
Increased activation of redox signalling by oxidative stress (OS) leads to myocyte 
hypertrophy and fibrosis and is a major non-haemodynamic contributor to LVH. 
Allopurinol can act as a potent anti-oxidant by inhibiting xanthine oxidase generated 
reactive oxygen species and has been shown to improve vascular OS and reduce LVH in 
other conditions such as chronic kidney disease, diabetes mellitus and ischaemic heart 
disease. The main aim of this thesis is to investigate whether allopurinol regresses LVH 
in patients with optimally treated, well-controlled hypertension.  
The trial design was a double-blind placebo-controlled study of 66 patients with 
hypertension and echocardiographic LVH. Patients were randomly allocated to 
allopurinol 600mg daily or placebo for 12 months. The primary outcome was the 
change in left ventricular mass detected by cardiac magnetic resonance imaging 
(CMRI) from baseline to the final visit. Secondary end-points assessed change in flow 
mediated dilation, augmentation index, pulse wave velocity, blood pressure control, 
biomarkers (Urate, High sensitivity C-Reactive Protein (HsCRP), Thiobarbituric acid 
reactive substances (TBARs), N-terminal prohormone B-Type Natriuretic Peptide (NT-
proBNP), Procollagen type I carboxy-terminal Propeptide (PICP) and soluble ST2 (sST2) 
and other CMRI parameters. 
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The two groups were well matched at baseline, importantly there were no statistically 
significant differences in gender, BMI, blood pressure, number of antihypertensive 
medications, urate (allopurinol 374.31 ± 85.63 µmol/L, placebo 347.28 ± 
108.33µmol/L) and LV mass. Allopurinol failed to regress left ventricular mass (LVM) 
compared to placebo (indexed LVM -0.18 ± 2.39 g/m1.7 vs -1.60 ± 1.60g/m1.7; p = 
0.009). OS markers (TBARs) increased from baseline in the cohort taking allopurinol 
compared to placebo (0.26 ± 0.85uM vs -0.34 ± 0.83uM; 0.007). No significant change 
was seen in FMD, AIx, PWV, BP, other biomarkers or the other CMRI parameters. 
Uric acid (UA) is a major antioxidant in human plasma but can become a pro-oxidant in 
certain conditions. By lowering uric acid with allopurinol, we have increased oxidative 
stress, altered the redox balance unfavourably and attenuating LVM regression 
compared to placebo. 
In conclusion, allopurinol prevented LVM regression in normo-uricaemic subjects with 
well controlled hypertension and LVH, potentially from increased oxidative stress 
secondary to the reduction of urate, an antioxidant. This trial demonstrates that LVM 
regression with allopurinol is not universal and future trials should carefully select 









1.1 Uric Acid Biology 
Uric acid is the end-product of the purine degradation pathway (Figure 1). At 
physiological pH ninety-eight percent is in the ionised form urate [4]. Extracellularly 
urate combines with sodium to form monosodium urate which has a solubility limit of 
380µmol/L. If this limit is exceeded it may lead to crystal deposition in tissues and 
joints that causes a profound inflammatory response called gout [4].   
During the Miocene epoch mutations occurred in the primate uricase gene rendering it 
inactive, thus humans cannot metabolise urate [5]. It has been proposed that there 
may be a genetic advantage of a non-functioning uricase gene due to the protection 
from oxidative damage or by maintaining blood pressure when dietary ingestion of salt 
was low [5-7].  
Urate levels are dictated by purine ingestion, de-novo synthesis in cells, excretion and 
the activity of xanthine oxidase [4]. Two thirds of uric acid is excreted by the kidneys 
however most (90%) is subsequently reabsorbed by the renal tubules, the remainder is 
eliminated by the gastrointestinal tract [4].   
Urate levels vary significantly within humans and tends to be higher in men, 
postmenopausal women (uricosuric effect of oestrogen), in subjects with reduced 
glomerular filtration rate (reduced excretion), obesity/insulin resistance (insulin 
stimulates resorption in the proximal tubule) and dyslipidaemia [5]. URAT1 is an anion 
transporter in the renal proximal tubule and is important in the resorption of urate, 
inhibited by probenecid and losartan explaining their uricosuric effects [4].  Loop and 




Figure 1 - Purine Degradation Pathway [9] 
 
1.2 Uric Acid as an Antioxidant 
Urate has been shown to be a powerful scavenger of singlet oxygen, peroxynitrite, 
peroxyl and hydroxyl radicals and is the main antioxidant in plasma [5, 6, 10]. 
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Furthermore, it can chelate transition metals, prevent the degradation of superoxide 
dismutase (SOD3) an enzyme critical for maintaining endothelial and vascular function 
and prevent nitration of tyrosine residues by peroxynitrite [5, 11]. Although this 
reaction produces a urate radical it is markedly less reactive and can be regenerated by 
ascorbate [5]. Urate can also reduce the oxo-heme oxidant formed when peroxide 
reacts with haemoglobin and protects erythrocytes from peroxidative damage 
preventing lysis [10]. Animal experiments have demonstrated that acute elevations in 
UA may provide anti-oxidant protection in the brain, liver and cardiovascular system 
[6]. Human studies have found that lowering UA with urate oxidase demonstrated no 
improvement in endothelial function or AIx in either healthy subjects or those with 
type II diabetes [12] and systemic administration of UA had no detrimental effect on 
measures of haemodynamics (AIx, BP, systemic vascular resistance index, baroreflex 
sensitivity and cardiac index) or nitric oxide dependent endothelial function in healthy 
male adults [13]. In fact intravenous administration of UA has been shown to has been 
shown to improve antioxidant function in healthy non-smokers at rest and exercise 
[14] and improve endothelial function in both type I diabetes mellitus and in smokers 
[15]. Co-infusion of uric acid with alteplase for acute stroke was compared to alteplase 
alone in the URICO-ICTUS trial [16]. Although statistically non-significant the addition 
of UA increased the percentage who had an outcome defined as “excellent” compared 
to the placebo arm (39% vs 33% respectively) with no increase in adverse events, 




1.3 Uric Acid as a Pro-Oxidant 
Although urate is an important antioxidant in serum it can have a pro-oxidant effect in 
certain conditions such as low levels of other anti-oxidants or intra-cellularly, therefore 
it should be thought of as a conditional pro-oxidant. In-vitro when UA is added to LDL 
then incubated with Cu2+ there is a delay in oxidation however when added later when 
α-tocopherol (the major antioxidant of LDL) levels were already reduced the oxidation 
rate was increased, an effect prevented by ascorbate [17]. Uric acid has also been 
found to stimulate NADPH oxidase activity and ROS generation in mature mouse 
adipocytes resulting in a decreased NO bioavailability, increased protein nitrosylation 
and lipid oxidation [18]. UA has also been shown to increase the generation of 
hydrogen peroxide and 8-isoprostane within rat vascular smooth muscle cells 
presumed to be mediated by the RAS system as the effect was attenuated by captopril 
or losartan [19]. UA reacts with peroxynitrite forming urate derived radicals, hence UA 
can inhibit peroxynitrite mediated effects, but this leads to the formation of the 
aminocarbonyl radical that can propagate oxidative reactions in particular the 
peroxynitrite mediated oxidation of liposomes and LDL [20].  
 
1.4 Uric Acid and Cardiovascular Risk 
High UA levels are associated with and can predict the development of cardiovascular 
diseases including hypertension and LVH [5, 6, 21]. Furthermore the first National 
Health and Nutrition Examination Survey (NHANES I) demonstrated a positive 
independent association with increasing serum UA and cardiovascular mortality [22]. 
Two large South-East Asian general population studies have observed a U-shaped 
curve for all-cause and cardiovascular mortality associated with serum UA levels [23, 
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24]. The first trial reported serum uric acid levels between 300 – 410umol/L had the 
lowest risk of events [23]. A more recent study demonstrated the same U shaped risk 
curve but described gender specific levels of serum UA above and below which risk 
increased (female 149 – 506umol/L, male 208 – 500umol/L) [24]. The PIUMA study 
found that the risk was J-shaped in both genders, the optimal urate in males was 
309umol/L and 232umol/L in females [25]. Evidence suggests that extremes of UA are 
detrimental, a mechanistic explanation could be the “urate redox shuttle” (Figure 2) 
described by Hayden et al where UA could act as an anti or pro-oxidant depending on 
the environmental milieu within an atherosclerotic plaque [26]. Finally a mendelian 
randomisation study found that after adjustment an genetically predicted increase in 
UA of 59umol/L increased the risk of cardiovascular death by 77% (HR, 1.77; 95% 





Figure 2 - The Urate Redox Shuttle [26] 
 
1.5 Allopurinol 
During their work with purine analogues in the 1950’s, Gertrude Elion and George 
Hitchins developed a hypoxanthine analogue (allopurinol) that blocked xanthine 
oxidase in the hope that it would improve the anti-cancer effects of 6-
mercaptopurine[28]. Realising it would also block the formation of uric acid it was 
subsequently tested in patients with hyperuricaemia and gout and was found to be 
clinically effective [28]. A discovery for which they were awarded the Nobel prize in 
1988 [29]. The drug was subsequently approved by Food and Drug Administration 
(FDA) in 1966 for the treatment of gout and remains to this day the first line agent for 
the treatment for primary and secondary hyperuricaemia [9, 29].  
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Allopurinol has the chemical structure 1,5-dihydro4H-pyrazolo[3,4-d]pyrimidin-4-one 
(Figure 3) [9]. It inhibits xanthine oxidase either directly as a competitive or non-
competitive inhibitor depending whether the concentrations are low or high 
respectively [9]. Most of its pharmacological action is via its main metabolite 
oxypurinol (Figure 3) due to the short half-life of allopurinol [9, 30]. In addition purine 
biosynthesis is reduced via feedback inhibition of hypoxanthine phosphoribosyl 
transferase [30].  
 
 
Figure 3 - Chemical structures of allopurinol and oxypurinol [9] 
 
Allopurinol reacts with XOR at Mo-Co to yield oxypurinol which binds to Mo inhibiting 
enzyme interaction with substrate [31]. Reduction of Mo-Co leads to the electron 
transfer to FAD and reduction oxygen i.e. enzyme turnover and ROS generation occurs 




1.5.1 Pharmacokinetics and Pharmacodynamics 
After oral ingestion allopurinol is detected in the blood after 30 to 60 minutes with a 
bioavailability of 67% to 90%. Peak plasma levels are achieved around one and a half 
hours, the t1/2 is 1.2 ± 0.3 hours and hence levels fall to undetectable levels within six 
hours [30, 32]. Peak oxypurinol levels occur around 3 to 5 hours but are more 
sustained as the t1/2 is 23.3 ± 6.0 hours [30, 32]. Allopurinol is negligibly bound by 
plasma proteins and the mean volume of distribution of allopurinol is 1.3L/kg and 
oxypurinol is 0.62 L/kg [30, 32]. 20% of allopurinol excreted in faeces, <10% in urine 
the remainder is converted to oxypurinol that is in turn excreted in the urine [30]. 
Mean renal clearance of allopurinol is 1.54mL/min/kg and oxypurinol 0.34mL/min/kg 
[32]. Patients with chronic kidney disease will consequently have higher plasma levels 
and will require a reduction in dose to avoid toxicity. 
 
1.5.2 Indication and Dosing 
Allopurinol is clinically indicated for lowering urate after episode(s) of gout or 
nephrolithiasis or in condition where there is a predictable risk such hyperuricaemia 
after chemotherapy, the so called “tumour lysis syndrome”[30]. The starting dose is 
100mg/day increasing up to a maximum of 900mg/day in divided doses, using the 
lowest dose to achieve satisfactory urate reduction, the usual clinical dosing is 300mg 
[30, 33]. Inhibition of XOR prevents the formation of ROS (Figure 1) and hence has the 
potential to reduce oxidative stress and is the hypothesised mechanism for 
improvements in LVM and vascular function in this study. Additional direct antioxidant 
effects have been demonstrated in experiments and using animal models within 
cardiomyocytes, kidney, liver and retinal tissue that may also contribute to improving 
26 
 
oxidative stress overall [34-38]. George et al demonstrated a steep dose response 
relationship between allopurinol and endothelial function, a dose of 600mg/day of 
allopurinol was found to completely abolished vascular oxidative stress in subjects 
with heart failure [39]. Subsequent studies in our institution have used 600mg safely  
[40-43]. Animal models have found additional free-radical scavenging effects at up to 
50mg/kg far beyond the XO inhibiting dose used by George et al[44], so it is unclear 
whether 600mg is the optimal dose or even higher doses could provide additional 
benefit. 
 
1.5.3 Side effects and Important Interactions 
Adverse reactions caused by allopurinol generally of a minor nature however the 
incidence is higher with renal or liver dysfunction and hence it should be used with 
care in these patients [30]. The most common side effect is a drug rash, fortunately 
hypersensitivity reactions known as DRESS are uncommon as is nausea and vomiting 
[30]. Stevens-Johnson syndrome or toxic epidermal necrolysis are rare, but serious 
complications [30]. Severe skin reactions are more frequent in those with a genetic 
predisposition such as HAN Chinese and those with HLA-B*5801 allele [45]. Important 
medication interactions include the inhibition of theophylline and the metabolism of 
azathioprine to 6-mercaptopurine. Both of the later medications are inactivated by the 





1.5.4 Evidence of use in Cardiovascular Disease 
1.5.4.1 Endothelial Dysfunction/Arterial Stiffness 
Endothelial dysfunction and increased vascular stiffness are predictors of adverse 
outcomes in HTN and there is some data that reversal influences prognosis [46, 47]. 
Improvement in endothelial function with allopurinol has been demonstrated in some 
pathologies but inconsistently in others, therefore the magnitude of the effect may be 
explained by the level of OS related to xanthine oxidase activity and/or urate level. 
Allopurinol improves endothelial function in hyperuricaemic subjects with chronic 
heart failure (CHF) [39, 48-50]. George et al also demonstrated this effect was due to a 
reduction in vascular oxidative stress and independent of uric acid lowering as 
probenecid a uricosuric agent had no effect on endothelial function [39]. Interestingly, 
Doehner et al found that an intra-arterial infusion of allopurinol had no effect on 
endothelial function in a small number (n=10) of normo-uricaemic CHF control patients 
[49]. Two of three randomised controlled trials (RCT)  in chronic kidney disease have 
demonstrated an improvement in endothelial function (FMD) with 300mg allopurinol 
[51-53], a meta-analysis of these studies concluded that allopurinol significantly 
improved endothelial function overall [54]. The same meta-analysis has failed to 
demonstrate an improvement in endothelial function in those with diabetes but cites 
heterogenicity, dosing and duration could have confounded the result [54]. There are 
few studies assessing the effect of allopurinol on endothelial function in essential 
hypertension in the absence of other significant comorbidities. In one such study by 
Cardillo et al oxypurinol failed to improve forearm blood flow to acetylcholine in 
subjects with hypertension but did in normotensives with dyslipidaemia, baseline 
urate level was unfortunately not reported in the study [55]. Mercuro et al found 
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allopurinol improved FMD in participants with increased uric acid levels and high 
cardiovascular risk (including a proportion of those with hypertension) [56] and 
healthy hyperuricaemics [57] taking allopurinol compared to normouricaemic controls. 
Allopurinol improves augmentation index (AIx) a measure of vascular stiffness in a 
number of pathologies from stroke [58], IHD [43, 59] and chronic kidney disease [53]. 
A recent meta-analysis concluded that treatment with allopurinol had a significant and 
favourable effect on AIx but not on PWV [60].  
1.5.4.2 Hypertension 
Feig et al (2008) conducted a small (n=30) randomised double blind, placebo-
controlled crossover study of untreated, uncomplicated, mildly hypertensive, 
hyperuricaemic (≥6.0mg/dL) adolescents.  Treatment with allopurinol resulted in a 
significant reduction in both urate, renin, systemic vascular resistance and BP (24-Hr 
systolic BP -6.3mmHg, diastolic BP -4.6mmHg) [61]. To answer whether reducing urate 
itself or xanthine oxidase generated ROS with allopurinol explained the results of the 
trial above, a study using probenecid, allopurinol and placebo in an obese pre-
hypertensive adolescent population was completed [62]. A significant and similar 
reduction in both BP and systemic vascular resistance compared to placebo was found 
in both treatment groups [62].  Kanbay et al have demonstrated an improvement in BP 
with allopurinol in a hypertensive hyperuricaemic and healthy adult populations 
compared to untreated normouricaemic controls [57, 63]. However many studies have 
not demonstrated an improvement in BP with treatment with allopurinol [64]. A meta-
analysis of 738 participants from 10 studies concluded that allopurinol treatment had a 
small and significant reduction systolic (3.3mmHg; 95% CI, 0.8-5.8mmHg; p = <0.001) 
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and diastolic (1.4mmHg; 95 CI, 0.1-2.7mmHg; p = < 0.04) blood pressure in 
hyperuricaemic subjects (Figure 4, Figure 5) [64].  
 
 





Figure 5 - Forrest Plot of the Effect of Allopurinol on Diastolic BP [64] 
 
1.5.4.3 Left Ventricular Hypertrophy Regression with Allopurinol/Oxypurinol 
The La Plata study observed a reduction in echocardiographic LV mass in a cohort with 
congestive heart failure after one-month treatment with oxypurinol, although non-
significant it was suggestive of a potential benefit of xanthine oxidase inhibition on left 
ventricular mass [65]. Three randomised controlled trials have demonstrated a 
significant reduction in LV mass measured by cardiac MRI after treatment with 
allopurinol for nine months. Kao et al demonstrated a significant reduction in indexed 
LV mass of 1.42 ± 4.67g/m2 in the intervention arm (allopurinol 300mg/day) versus an 
increase of 1.28 ± 4.45g/m2 (p = 0.036), in subjects with stage 3 chronic kidney disease 
and LVH [53]. Rekhraj et al found high dose allopurinol (600mg/day) regressed LV mass 
compared to placebo in a cohort with ischaemic heart disease (-2.2 ± 2.78g/m2 versus -
0.53 ± 2.5g/m2) (p = 0.023) [59]. Finally, Szwejkowski et al also demonstrated a 
reduction in LVM index with allopurinol (600mg/day) versus placebo (-1.32 ± 2.84g/m2 
versus +0.65 ± 3.07g/m2) (p = 0.017) [40]. 
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1.6 Alternative Urate Lowering Medications 
Febuxostat is a potent, non-purine selective inhibitor of XO, indicated for the 
treatment of gout and tumour lysis syndrome in those intolerant to allopurinol[66]. 
The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) and 
Febuxostat versus Allopurinol Controlled Trial (FACT) trials demonstrated that 
febuxostat were superior at lowering serum UA than allopurinol [67, 68]. Although 
more effective at lowering UA, there was no significant difference in gout flares 
between the allopurinol or febuxostat [67]. Interestingly the APEX trial a numerically 
higher but statistically non-significant incidence of cardiovascular events in the 
febuxostat arm. This has been investigated further in the Cardiovascular Safety of 
Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities 
(CARES) trial and found a significantly higher all-cause and cardiovascular mortality in 
patients with gout and cardiovascular disease treated with febuxostat compared to 
allopurinol [69]. Hence febuxostat is not recommended for use in ischaemic heart 
disease or heart failure [66]. Although a mechanism has not be identified by the 
authors it is possible excessive UA reduction may contribute.  
Probenecid and Benzbromarone are potent uricosuric agents, can be used as an 
alternative to allopurinol for the treatment of gout, but have been replaced by 
allopurinol and febuxostat [70, 71]. 
 
1.7 Oxidative Stress 
Reactive oxygen species (ROS) consist of radical and non-radical atoms or molecules 
derived from oxygen. A radical is characterised by the presence of an unpaired 
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electron(s) and is unstable and highly reactive. Examples of radicals are superoxide, 
peroxide and hydroxyl groups. Non-radical ROS such as hydrogen peroxide and 
peroxynitrite are also powerful oxidants and react readily with surrounding molecules 
[3, 72]. ROS are produced in small amounts during the normal biochemical processes 
of the body and are required for normal “redox signalling” pathways, host immune 
response [3, 73], and at normal levels are non-pathogenic [74]. Oxidative stress (OS) is 
the term used when an excess of ROS are generated and/or antioxidant capacity is 
decreased [73] and has important pathological consequences (Figure 6).  
 
 
Figure 6 - Oxidative Stress Effects [74] 
 
Important endogenous sources of ROS include xanthine oxidase (XO), NADPH oxidases, 
uncoupling of nitric oxide synthase (NOS) and from mitochondria during oxidative 
phosphorylation [75]. Homeostasis is maintained by antioxidant defences balancing 
the endogenous/exogenous sources of ROS and are broadly divided into enzymatic 
and non-enzymatic antioxidants. Oxidative stress is implicated in a number of 
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cardiovascular conditions such as atherosclerosis [76], heart failure [77], myocardial 
infarction, hypertension [75] and left ventricular hypertrophy [73]. 
 
1.7.1 Xanthine Oxidoreductase 
Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme [78] that consists of 
two interchangeable forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH) 
[31], the former is inhibited by allopurinol and is the primary focus of this thesis. Both 
forms of XOR catalyse the terminal steps of the purine degradation pathway (Figure 1).  
The XOR enzyme is a homodimer consisting of catalytically independent subunits, each 
subunit contains three domains each containing a specific cofactor(s), molybdopterin 
(Mo-Co), flavin adenine dinucleotide (FAD) and two iron-sulphur (Fe2-S2) clusters [31].  
Mo-Co is the site of purine oxidation, FAD enables NAD+ and O2 reduction, and Fe2-S2 





Figure 7 - Actions of XOR enzymes [29] 
 
XO exhibits little reactivity with NAD+ and hence transfers purine derived electrons 
only to oxygen generating superoxide and hydrogen peroxide [29]. XDH in contrast can 
reduce NAD+ or oxygen but has a higher affinity for the former due to rapid and tight 
binding, but only when NAD+ is available [31]. When NAD+ is in short supply XDH acts 
as a NADH oxidase subsequently reducing oxygen to superoxide, however XDH reacts 
slowly with oxygen so the rate of superoxide generation is 25% that of XO [31]. ROS 
generated by purine metabolism can be converted to other ROS such as the 
peroxynitrite or the highly reactive hydroxyl radical formed by the Haber-Weiss 







     
 
Compared to other mammals, XOR is in relatively low abundance and activity in 
humans, even between individuals there can be as much as a threefold variation of 
activity [31, 54]. The highest levels of XOR activity have been identified in human liver, 
small intestine and mammary gland [79]. Low levels of XOR protein/activity have been 
demonstrated in the human heart and endothelium [31]. Although basal gene 
expression in humans is low a number factors that regulate transcription have been 
identified (Figure 9), and increased XO activity has been demonstrated in a number of 
cardiovascular conditions including dilated cardiomyopathy [80], heart failure [81], 
pressure overload hypertrophy [73] and hypertension [82]. 
H2O2 + O2˙  ̄→˙OH + OH- +1O2 




Figure 9 - Regulators of XOR gene expression [31] 
 
Under certain conditions such as inflammation/hypoxia reversible conversion of XDH 
to XO by oxidation of thiol groups (Cys535, Cys992) and/or irreversible conversion by 
proteolysis occurs (Figure 7) enhancing ROS generation [31]. When oxygen tension and 
pH are normal the predominant ROS generated by XO is hydrogen peroxide, 
furthermore there is an inverse relationship between oxygen tension and XO 
generated hydrogen peroxide further enhanced by a reduction in pH [29]. The 
relationship between oxygen tension and XOR activity is clearly established but the 
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mechanism is poorly understood but thought to involve both post-translational 
modification, transcriptional regulation or both [29]. XOR is released  into the 
circulation in response to hypoxia/ischaemia of endothelium where it is irreversibly 
changed to XO [29]. Plasma XO has an affinity for vascular endothelial 
glycosaminoglycans (GAGs) and provides a mechanism for XO generated ROS in 
vascular beds [29].  Peroxynitrite a potent oxidant, is formed by the reaction of 
superoxide with NO, in hypoxic and acidic conditions XO can generate both molecules 
and therefore potentiate the formation of peroxynitrite (Figure 10) [29, 31]. As 
discussed previously NADPH oxidase generated ROS can further amplify ROS 
generation by the activation of XO [81].  
 
 
Figure 10 - XOR catalysed production of NO and peroxynitrite [78] 
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1.7.2 NADPH Oxidases 
NADPH oxidases catalyse electron transfer from NADPH to molecular oxygen, resulting 
in superoxide [81] a reaction that has been found in a variety of cells  including 
vascular smooth muscle and endothelial cells, fibroblasts and cardiomyocytes [81]. 
Enzyme activity is stimulated by angiotensin II (ATII), endothelin-1 (ET-1), cytokines, 
growth factors, oxidised low density lipoprotein (LDL), sheer stress and mechanical 
stretch [81]. ROS generated can lead to further increase in reactive oxygen species by 
activation of xanthine oxidase and NOS uncoupling [81]. NADPH oxidase is a major 
source of ROS involved in redox signalling and is important  factor in the 
pathophysiology of hypertension, atherosclerosis, heart failure and left ventricular 
hypertrophy [81, 83].  ACE-I and ARBs are highly effective inhibitors of ATII dependent 
NADPH oxidase activation, have been shown to improve endothelial function and 
regress arterial remodelling and LVH, and are used routinely in heart failure and 
hypertension [81, 84-87]. 
 
1.7.3 Nitric Oxidase Uncoupling 
Nitric oxide synthase (NOS) catalyses the reaction of L-arginine, O2 and NADPH forming 
L-citrulline and nitric oxide (NO). It exists in three isoforms all of which have been 
detected in cardiomyocytes, vascular smooth muscle and vascular endothelial cells 
[88]. A number of cofactors are required for the reaction including tetrahydrobiopterin 
(BH4), calmodulin, flavin mononucleotide and flavin adenine dinucleotide [88]. Under 
normal physiological conditions NO acts as a signalling molecule activating soluble 
guanylyl cyclase (sGC) then cyclic guanosine monophosphate (cGMP) [89]. cGMP 
exerts its actions on the cardiovascular system via cGMP dependent protein kinases 
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(PKG) and cGMP regulated phosphodiesterase’s (PDE) [88].  cGMP-PKG signalling 
stimulates cell proliferation and increases permeability in the vascular endothelium, 
inhibits cell proliferation and mediates vasorelaxation in vascular smooth muscle and 
in the cardiomyocyte inhibits hypertrophy, modulates contractility and mediates 
apoptosis in all (Figure 11)[88].  
 
 
Figure 11 - cGMP-PKG actions [88] 
 
[90]. cGMP-PDEs are regulated by and catabolise cyclic nucleotides [88]. There are 11 
isoenzymes of which a number are expressed in cardiomyocytes, vascular endothelial 
and vascular smooth muscle cells [88]. PDE5 has been implicated as an important 
regulator of cGMP in cardiac myocyte hypertrophic response to pressure-overload 
[88]When BH4 or L-arginine is deficient, or BH4 is oxidised NOS becomes “uncoupled” 
and generates superoxide[81].  
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1.7.4 Oxidative Phosphorylation 
A small amount of superoxide is generated during oxidative phosphorylation in the 
mitochondria [81]. Usually converted to water by the action of superoxide dismutase, 
glutathione peroxidase and catalase, under pathological conditions the hydroxyl 
radical can be formed [81].  
 
1.7.5 Enzymatic/Non-Enzymatic Antioxidant defences 
Superoxide dismutase (SOD) is known to exist in three forms [91], manganese 
(MnSOD), copper (CuSOD) and zinc superoxide dismutase (ZnSOD) [92]. MnSOD 
activity accounts for the majority of the SOD activity in the heart [91]. Present in the 
mitochondria it converts superoxide generated from oxidative phosphorylation to 
hydrogen peroxide (Figure 12) [91]. Genetically modified mice without MnSOD activity 
die from a dilated cardiomyopathy soon after birth and no inherited diseases have 
been found lacking MnSOD suggesting it is a critical enzyme [91]. Expression of MnSOD 
is induced by oxidative stress [93]. CuSOD and ZnSOD are extracellular and are less 
important as transgenic mice lacking this activity develop normally but appear to have 





Figure 12 - Enzymatic Antioxidant Defences [91] 
 
Glutathione peroxidases (GPX) and catalase (CAT) are the enzymes responsible for the 
degradation of hydrogen peroxide generated by SOD to water (Figure 12). Reduced 
glutathione is oxidised [91] then recycled by glutathione reductase by the conversion 
of NADPH to NADP+ in the pentose phosphate pathway [91]. Catalase also detoxifies 
phenols and alcohols via coupled reaction with hydrogen peroxide [93]. 
Thioredoxin in mammalian cells reduce peroxides directly [93] and thioredoxin 
reductase is involved in the regeneration of ubiquinone, lipoic acid and ascorbic acid 
which are important antioxidants [3]. Complete deletion of the thioredoxin reductase 
gene (TrxR2) caused foetal death in mice and TrxR2- deficient mice died shortly after 
birth from dilated cardiomyopathy [94].  
Important non-enzymatic antioxidants include vitamins C and E, B-carotene, 




Primary (essential) hypertension, hereafter referred to as hypertension (HTN) develops 
as a consequence of the interaction between environmental and genetic factors and 
accounts for most patients with an elevated blood pressure. Secondary hypertension 
has recognised aetiology and is diagnosed in the remaining 5-10% [95]. Current NICE 
guidelines definitions of the stages of hypertension are listed below [96]. 
 
• Stage 1 HTN - Clinic BP of ≥140/90 and ABPM ≥135/85mmHg.  
• Stage 2 HTN - Clinic BP of ≥160/100 and ABPM ≥150/95mmHg. 
• Severe HTN - Clinic systolic pressure ≥180mmHg or diastolic BP ≥110mmHg. 
 
Hypertension is a leading preventable risk factor for cardiovascular disease (ischaemic 
and haemorrhagic stroke, coronary artery disease, heart failure, peripheral arterial 
disease and renal disease) worldwide[95]. Although a “normal” BP is difficult to define, 
the observed risk is strong, graded, continuous and positively related to the degree of 
hypertension [95]. The development of target organ damage e.g. LVH represents a 
strong and independent predictor of risk and should prompt intensification of 
treatment [97]. The term resistant hypertension (RHTN) is used when a blood pressure 
remains above target despite the use of optimal doses of three antihypertensive 
agents of different classes (ideally one of the agents should be a diuretic) [98]. Post 
hoc analysis of clinical trials and observational studies have estimated a prevalence of 
10-20% of the hypertensive population [99]. A retrospective cohort study of 205,750 
subjects with hypertension found a significantly increased cardiovascular risk 
compared to those with controlled BP on less than three antihypertensive drugs (HR 
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1.47; 95% CI 1.33-1.62, p = <0.001) [100]. This excess risk could in part be attributed to 
the high prevalence of LVH in this group, estimated as between 55-81% of patients 
with RHTN[101]. Alternative therapies are required to address the additional risk as 
conventional treatments are not fully effective. 
 
1.8.1 Epidemiology 
Several factors have been recognised that influence the development of HTN e.g. 
gender, race, nutrition, alcohol consumption and physical exercise. The influence of 
age however has been consistently demonstrated to be positively correlated with 
systolic BP [102]. The Framingham study demonstrated this relationship of age and 
systolic BP (Figure 13). Diastolic BP rises with age until around the fifth decade and 





Figure 13- Framingham study trends in BP with age [103]  
 
 The prevalence of hypertension in the England was 32% in men and 27% in women in 
2014 and relatively static (Figure 14)[104]. Although the percentage well controlled 
has increased over the last decade to approximately 30% the remainder are either 




Figure 14 - Prevalence of HTN England [104] 
 
1.8.2 Pathophysiology 
The pathophysiology of hypertension is complex, multifactorial and incompletely 
understood. Broadly there is an interaction between environment and susceptibility 
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Complex genetic traits are defined as those without a simple “Mendelian” one-to-one 
relationship between genotype and phenotype, and are seen in hypertension and 
LVH[105].  A study in the 1960’s by Mial et al. surmised that in a general population 
the majority of systolic and diastolic variation was secondary to environmental factors 
but that a multifactorial pattern of inheritance could explain the remaining variability 
[106]. Observations that a family history of HTN increases the risk fourfold support a 
genetic role in its pathophysiology [107]. Over forty single nucleotide polymorphisms 
(SNPs) that increase systolic and diastolic BP with genome wide significance (GWAS) 
have been identified [107]. The effect size of this genetic variation is small and doesn’t 
fully explain the heritability of hypertension however it is expected that undiscovered 
loci with larger effect sizes may do so in the future [107]. 
 
1.8.2.2 “Environmental” Triggers 
Observational studies have independently associated increased body mass index, 
elevated salt and alcohol consumption, and reduced physical activity with an increased 
risk of developing HTN [108]. Interventional studies using weight loss[109], increased 
exercise [110], diet modification [111], reduced sodium [112] and alcohol intake [113] 
all lower BP and support causal role of environmental factors in the pathogenesis of 
hypertension. The expected age related increase in BP in “Westernised” populations 
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doesn’t occur in primitive isolated societies further supporting a strong environmental 
influence on BP [114]. 
 
1.8.2.3 Renin Angiotensin System  
The renin angiotensin system (RAS) is a hormonal system important in the regulation 
of normal BP and in the pathogenesis of hypertension (Figure 15). Since the initial 
discovery of a factor (renin) released by the kidneys that controlled BP by Tigerstedt 
and Bergman in 1898, the knowledge and complexity of this system has 
increased[115]. The system can be broadly divided into the “classical” systemic and 





Figure 15 - Renin angiotensin aldosterone system [116] 
 
primary physiological function of the RAS is to control vascular tone and water 
homeostasis [111].  Renin is released from the juxtaglomerular apparatus after 
stimulation of the afferent arteriolar baroreceptors by hypoperfusion or detection of 
reduced sodium chloride in the distal tubule and vice versa [110]. In addition, β2-
adrenergic receptor stimulation by norepinephrine released from the renal 
sympathetic neurones also leads to renin release [110]. Angiotensinogen is cleaved by 
renin to form angiotensin I, which is then converted to angiotensin II (ATII) by 
angiotensin converting enzyme (ACE). ACE simultaneously degrades vasodilator 
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peptides such as bradykinin [110]. ATII is the major effector peptide of the RAS and 
stimulates G-protein coupled receptors AT1 and AT2 which generally have opposing 
effects [110], animal models suggest an imbalance of receptor expression that might in 
part explain why AT1R action dominates. AT1R is widely distributed in the heart, 
kidneys and vasculature and stimulation has several effects (Table 1) that includes the 
generation of ROS [114]. Infusions of ATII into rats has been shown to increase both BP 
and doubled vascular superoxide formation that was associated with impaired 
vasodilation, that was reversed by the administration of Losartan [117]. Although ACE 
is predominantly expressed in high concentration on the pulmonary vasculature [118] 
it can be found in the endothelium of vasculature in all tissues and nonendothelial 
parenchymal cells in the heart, kidney and inflammatory cells [119].  
 
Table 1 - Effects of ATII via AT1R (adapted) [114] 
 
Vasoconstriction 
Cardiac & Vascular Remodelling 
SNS activation 
Superoxide Generation 










Synthesis of ATII within the cell or interstitium with function and regulation 
independent of or in conjunction with of circulating system has been demonstrated 
with both autocrine and paracrine effects [115]. Stretching rat cardiomyocytes in vitro 
causes hypertrophy in the absence of neuronal and hormonal factors [120],[121]. 
Several candidate factors have been demonstrated to cause hypertrophy in-vitro, but 
evidence suggests that ATII is a critical mediator for stretch induced response in 
cardiomyocytes [122]. ACE induction occurs in conditions of increased wall stress (i.e. 
pressure overloaded) and effects changes in fibroblasts, myocytes and the vasculature 
[119]. Endothelial ACE is upregulated by vascular injury from a variety of insults 
including hypertension leading to a reduction in bradykinin and an increase in local ATII 
[119]. Aldosterone increases resorption of sodium in the cortical collecting duct but 
also stimulates vascular remodelling by smooth muscle cell proliferation, vascular 
extracellular matrix deposition and increases OS [95]. 
 
1.8.2.4 Autonomic nervous system. 
The autonomic nervous system has an important physiological role controlling blood 
pressure by its effect on cardiac output and peripheral resistance in healthy individuals 
(Figure 16) [123]. Sympathetic overdrive and impaired vagal response exists in those 
predisposed to developing hypertension and in those with hypertension, and is 
thought to have a role in both the pathogenesis and end organ damage associated 
with hypertension [123]. Furthermore the RAS and SNS have been shown to interact in 
a positive feedback loop to further augment BP [124]. Norepinephrine has been 
detected at higher levels in essential hypertensive patients than in healthy controls in 
most studies [125]. Studies using radiolabelled norepinephrine have demonstrated 
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that the elevated levels are caused by increased release from nerve terminals and is 
most pronounced in the brain, kidney and heart [125]. Microneurographic 
measurement of muscle sympathetic nerve activity (MSNA) provides a valid measure 
of resting sympathetic nerve activity to muscle vasculature that contributes to 
peripheral resistance and hence BP [126]. Elevated MSNA has been demonstrated as a 
generalised phenomenon in hypertension [123], progresses with severity [127], is 
more pronounced in those with organ damage (i.e. LVH, LV systolic and diastolic 
dysfunction) and resistance to treatment [123]. MSNA is increased in normotensive 
obese patients and even more marked in obese hypertensive subjects thought to be 
explained by elevated insulin, renin, leptin and endothelin secretion that have SNS 
stimulating effect [128]. In a number of animal experiments renal denervation 
prevents or reduces the severity of hypertension [129], human trials initially 
demonstrating promise [130], [131] but may have been biased by trial design and 
SYMPLICITY HTN-3 trial did not show a reduction of systolic BP [132].  
A reduction in vagal tone and elevated SNS activity have been associated with the 
development of hypertension in animal models [123] and evidence of an impaired 
vagal response has also been demonstrated in human studies. Heart rate and cardiac 
output remained significantly higher after intravenous beta-blocker in hyperkinetic (i.e. 
high resting cardiac output and heart rate) borderline hypertension compared to 
controls but atropine administration equalised its effect [133]. Another study found 
atropine had a smaller effect on heart rate in young borderline hypertension than 
controls [134]. Impairment of baroreflex cardiovascular control has also been 
demonstrated in lean patients with hypertension, obese normotensives and of greater 
magnitude obese subjects with hypertension [128]. Further evidence of 
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parasympathetic dysfunction with hypertension comes from the observation of a 
gradual reduction of bradycardia/ tachycardia responses to baroreceptor 
stimulation/deactivation with increasing severity of hypertension compared to 
normotensives [123]. Baroreceptor activation therapy has been demonstrated to be 
effective in long term reduction of BP in RHTN patients [135]. Supporting evidence that 
the SNS has a role in vascular and cardiac remodelling comes from animal models. 
Stimulation of α1-adrenoreceptor in rat aorta smooth muscle cells induced 
hypertrophy [136]. Sympathetic denervation of rabbit arteries decreased weight, wall 
thickness and contractility [137].  
 
 
Figure 16 - Sympathetic Nervous System [138] 
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1.8.2.5 Insulin Resistance 
Insulin resistance a cardinal feature of the metabolic syndrome has been 
demonstrated in untreated hypertensive patients with normal body weight and 
glucose intolerance [139]. Insulin resistance impairs the protective effects of the 
insulin stimulated NO pathway instead causing vasoconstriction, vascular smooth 
muscle cell proliferation, inflammation, sodium resorption and sympathetic nervous 
system activation via the mitogen-activated protein kinase pathway (MAPK) [140]. 
 
1.8.2.6 Endothelial Function 
Increased peripheral resistance is a cardinal feature of established hypertension[114], 
caused by functional (endothelial dysfunction), structural (vascular remodelling) and 
mechanical alterations (vascular stiffness) of resistance arteries [87].  
The endothelium of blood vessels is a paracrine organ that regulates vascular tone via 
vasodilators (nitric oxide, natriuretic peptides, prostacyclin) and vasoconstrictors 
(endothelin, angiotensin II)[95, 141]. Nitric oxide (NO) additionally protects the 
vasculature from atherosclerosis, thrombosis and inflammation by inhibiting platelet 
adhesion and aggregation, leucocyte adhesion and proliferation of vascular smooth 
muscle cells [141, 142]. Hypertension induces ROS generation in the vascular wall, 
predominantly from NADPH oxidases, but also from xanthine oxidase, cyclooxygenases 
and reduced superoxide dismutase activity (Figure 17)[95, 142]. Excess superoxide 
oxidises BH4, uncouples endothelial nitric oxide synthase, reacts with NO to form the 
pro-inflammatory oxidant peroxynitrite with the effects of further ROS generation, 
54 
 




Figure 17 - Vascular ROS [143] 
 
Endothelial dysfunction is an important factor in subjects with hypertension and has 
been demonstrated in the early stages [142, 144-146]. A number of small trials have 
demonstrated an inverse relationship with endothelial function and LVM [147-149] but 
not all [146]. The largest study to support this relationship was a sub-group analysis of 
2447 of the Multi-Ethnic Study of Atherosclerosis trial which found that a 0.5g/m2 
reduction in indexed LVM improved flow mediated dilation by 1% after adjustment 




1.8.2.7 Vascular Remodelling & Stiffness 
Structural remodelling of resistance arteries occurs early and has been demonstrated 
in patients with only mild hypertension, preceding other clinically detectable target 
organ damage [144, 151]. Inward eutrophic remodelling is the usual pattern in 
essential HTN where there is narrowing of the lumen but preservation of the medial 
cross-sectional area of small arteries [151]. In secondary hypertension and conditions 
where the endothelin system is activated (salt-dependent/malignant hypertension, 
diabetes) inward hypertrophic remodelling is found, characterised by an increase in 
the media to lumen ratio [151]. The cell volume and number of vascular smooth 
muscle cells (VSMC) are similar to normotensives in eutrophic remodelling but there 
are changes in the extra cellular matrix [151, 152]. Increased type I and III collagen 
mRNA and protein synthesis has been detected within fibroblasts and increased 
collagen has been found within the media of resistance arteries [87]. ROS are of critical 
importance in vascular remodelling, predominantly from NADPH oxidase, and to a 
lesser degree xanthine oxidase [153]. ROS activate redox sensitive signalling molecules 
causing VSMC contraction, cell growth, apoptosis and increased ECM [154]. 
Angiotensin II is a major stimulant of vascular remodelling (Figure 18), increasing 
collagen formation by p38 mitogen activated-protein kinase (MAPK) and extracellular 
signal regulated protein kinase (ERK) pathways[155] and attenuating MMP activity 
[87]. Furthermore ATII activates redox sensitive genes NFkB, AP-1 that upregulate 
adhesion molecules, chemokines and monocyte/macrophage recruitment in the 
vascular wall causing inflammation [156]. Angiotensin converting enzyme inhibitors 
and AT1R antagonists have been demonstrated to regress arterial remodelling, 
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improve endothelial function, reduce vasomotor tone, lessen inflammation and 
normalise aberrant signalling in vascular smooth muscle [87]. 
 
 
Figure 18 - Vascular remodelling and the RAS [153] 
 
Fragmentation of elastin fibres, accumulation of extracellular collagen, inflammation, 
calcification and medial smooth muscle necrosis leads to reduced compliance and 
dispensability of central conduit vessels, termed vascular stiffness [47] and can 
develop in advanced hypertension [156].  Pulse wave velocity (PWV) is the rate of 
propagation of a pulse of blood though the arterial circulation and can be used as a 
direct measure of central vascular stiffness that increases with age and in those with 
cardiovascular risk factors including hypertension [157].  Increased aortic PWV is a 
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predictor of adverse outcomes in HTN [47], with an independent association with 
cardiovascular events [158], all cause and CV mortality [159]. Pulse pressure is a 
composite of the forward pressure created by ventricular contraction and the reflected 
retrograde waves (Figure 19)[160]. Reflection occurs at branch points or sites of 
impedance mismatch, as vessels stiffen the PWV increases and the reflected wave 





Figure 19 - Incidental, reflected and resultant pressure waveform [161] 
 
Isolated systolic hypertension is the usual form over 55 years of age (Figure 13) [157] 
and confers greater CV risk than an elevated diastolic pressure [162]. Increased central 
pulse pressure has the effect of increasing afterload and hence promoting LVH, 
vascular remodelling and atherosclerosis [47]. 
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Augmentation index (AIx) is the percentage of the pulse pressure caused by the 
reflected pulse wave and is a surrogate marker of vascular stiffness and a measure of 
the ventricular load [157]. Although AIx has been demonstrated to correlate with both 
cardiovascular risk scoring (r= 0.35 – 0.685) [163] and with CV risk factors (r=0.604) 
[164] it has failed to predict risk in a hypertensive cohort [165]. AIx does however have 
an independent and positive correlation with left ventricular mass index in 
hypertensive and normotensive subjects [166, 167]. A twin study using qualitative 
genetic modelling concluded the inheritability of AIx was 37%, more striking than that 
for BP (13-25%) with only a small percent attributed to other potential genetic 
influences of AIx (i.e. height, heart rate, mean arterial pressure) [168]. Although there 
is a linear correlation between PWV and AIx (r = 0.41), the latter is influenced by BP, 
heart rate, gender, age, height and vasoactive drugs independent of changes of 
vascular stiffness [157]. 
ACE-I, ARB, CCB and MRA all reduce vascular stiffness thought to be either directly by 
reducing wall stress or reduced impedance in peripheral arteries delaying wave 
reflection or indirectly by anti-fibrotic actions [151]. A number of RCTs have been 
conducted to assess the effect of allopurinol on PWV and AIx, with conflicting results 
[60]. A meta-analysis concluded that Allopurinol improved AIx but not PWV [60]. 
 
1.8.2.8 Uric Acid and Hypertension 
An elevated uric acid is a strong independent predictor of hypertension in almost every 
published study [7]. A meta-analysis comprising 55,607 subjects from North America. 
Asia and Europe, found an adjusted risk ratio of 1.41 (95% CI, 1.23-1.58) for the 
development of hypertension if hyperuricaemic, a relationship that is more 
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pronounced in younger individuals [169]. Support of a causal relationship initially came 
from animal models. When rats were treated with an uricase inhibitor, developed an 
elevated blood pressure attenuated with xanthine oxidase inhibition or uricosuric 
agents [7].  
Human studies have demonstrated that elevated uric acid after consumption of large 
quantities of fructose lead to an elevated blood pressure, an effect prevented by 
treatment with allopurinol [170].  A two-phase mechanism has been proposed (Figure 
20). In the first phase uric acid-dependent activation of the rennin-angiotensin system 
occurs leading to increased oxidative stress, reduced endothelial nitric oxide and salt 
resistant hypertension [171, 172]. Over time altered renal microvascular changes occur 




Figure 20 - Model of development of hyperuricaemic induced hypertension [171] 
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The mechanism is the entry of uric acid via the URAT-1 channel followed by kinase and 
nuclear transcription factor activation the production of cyclo-oxygenase 2, growth 
factors, inflammatory proteins (CRP, monocyte chemoattractant protein-1) and 
ultimately vascular smooth muscle proliferation [171]. Feig et al proposed this model 
explained the greater association of elevated uric acid with hypertension and youth 
[171]. 
 
1.8.3 Treatment of HTN (NICE Guidelines) 
The treatment of hypertension consists of lifestyle measures and/or antihypertensive 
medications. Lifestyle measures include advice regarding smoking cessation, improving 
diet, weight loss, increasing exercise, reducing alcohol, salt and caffeine consumption. 
Pharmacological interventions are indicated in patients with stage I hypertension and 
target organ damage, cardiovascular or renal disease, those with diabetes or those 
with a 10-year CV risk >20% and all patients with stage 2 or severe hypertension. 
Medications are added in a stepwise approach illustrated in Figure 21 aiming for a 
target office BP of <140/90mmHg or ambulatory (ABPM) or home BP monitoring 
(HBPM)<135/95mmHg in patients under 80 years of age. An office BP of 












1.9 Left Ventricular Hypertrophy 
 
1.9.1 LVH Prevalence and Risk Factors 
1.9.1.1 General Population 
The prevalence of LVH depends on the population studied and the criteria by which 
you define it. Over time the threshold for diagnosing LVH by echo has fallen and hence 
assessing the change of prevalence is challenging. The Framingham heart study, a 
prospective epidemiological study of the residents of Framingham, Massachusetts 
investigated the prevalence of LVH.  Initial studies using ECG found 3% of subjects 
fulfilled criteria for LVH [173]. Echocardiography of 4976 subjects found 16% of men 
and 19% of women had LVH [174].  A multivariate analysis demonstrated significant 
independent associations with age, systolic BP, obesity, valve disease, antihypertensive 
medication, angina and myocardial infarction were demonstrated [174]. A marked 
increase in the prevalence with age was found (Figure 22), occurring in 6% under 30 to 





Figure 22 - Prevalence of LVH with Age [174] 
(Male dashed line, Female solid line) 
 
A more contemporary prospective observational study 3287 subjects from Norway 
found 14.9% of men and 9.1% of females has LVH. Independent risk factors and odds 
ratios are shown in Figure 23[175]. The PAMELA study found that a serum uric acid 
>5.1mg/dL at baseline predicted the development of LVH over ten years after 





Figure 23 - Independent risk factors for LVH [175] 
 
1.9.1.2 LVH Prevalence in Hypertension 
A review of the prevalence of echocardiographic LVH in treated and untreated 
hypertensive patients was conducted by Cuspidi et al [176]. Thirty studies, totalling 
37,770 patients from the first decade of this century were selected. Using lower 
thresholds for LVH diagnosis the prevalence of LVH in the pooled population was 
40.9%. There was significant heterogeneity between studies and criteria by which LVH 
was diagnosed varied. The prevalence in untreated hypertension was 19-48%, 
increasing to 58-77% in the “highest risk” populations that included severe/resistant 
hypertension and those with ECG-LVH. LVH persists even in well treated hypertensive 
patients, 17% of subjects from the PAMELA population had LVH despite a mean BP of 
120.2±8.5/75.7±4.9mmHg [177]. Observational data has found a continuous 
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relationship between age, systolic BP and LVH (Figure 24) [174]. LVM correlates more 
closely with 24 hour mean ambulatory BP (ABPM) than clinic BP [178]. 
 
 
Figure 24 - LVH prevalence with age and BP quartiles [174] 
 
1.9.1.3 Genetic factors 
Epidemiological studies have demonstrated that <50% of the variance in left 
ventricular mass can be explained by conventional risk factors [168]. Heritability of LVH 
is supported evidence from observational studies in general populations [179], sibling 
[180] and twin studies [181, 182]. In humans there is evidence of an association of 
several genes related to hormones (i.e. ATII, ANP, catecholamine’s, and 
mineralocorticoids) or the cardiomyocyte (i.e. myosin, heat shock proteins, growth 
factors) but a causal relationship has been difficult to establish [183]. Several single 
nucleotide polymorphisms (SNPs) have been identified with associations to LVH in  
genome wide association studies (GWAS) but have not been replicated in other 
populations [184].  It is thought that multiple variants, each with modest effect size are 
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involved in modulating LVM [185]. Genetic polymorphism of the RAS and other 
pathways have been implicated in the development of LVH and may account for a 
significant variance in LV mass independent of BP [186] and response to treatment 
[187].  
 
1.9.2 Risk of LVH 
Echocardiographic LVH was associated with an increased cardiovascular morbidity and 
mortality even after adjustment for other major risk factors in the Framingham 
population [188]. Increased risk has also been consistently demonstrated in specific 
pathologies such as end-stage renal failure [189], hypertension [190], ischaemic heart 
disease [191] and normotensives [192]. A review of 20 studies assessing the risk of CV 
events with ECG or echocardiographic LVH (total of  48,545 subjects) calculated an 
overall adjusted mean risk ratio of CV morbidity of 2.3 and all-cause mortality of 2.5 
[193]. A head to head study of 1089 black participants demonstrated that LVH 
independently conferred a higher risk of death (RR 2.4; 95% CI 1.7 to 3.2) than multi-
vessel coronary artery disease (RR 1.6; 95% CI 1.1 to 2.2) or reduced LV function (EF 
<45%) (RR 2.0; 95% CI, 1.4-2.7) [194]. Schiallaci et al found a positive linear increase in 
risk of CV events and all-cause mortality across the quintiles of LVM in a cohort of 1925 
uncomplicated hypertensive patients (Figure 25). After accounting for baseline 
differences between quintiles, risk was significantly elevated from quintile 3 i.e. males 
119.8g/m2, females 101.8g/m2. This roughly corresponds to the values currently used 





Figure 25 - Relationship of LVM and risk in Essential HTN [195] 
 
Several distinct patterns of abnormal LV geometry have been described (Figure 26) and 
can provide additional prognostic information. Those with hypertension and normal 
geometry are at the lowest risk which increases progressively from concentric 
remodelling through eccentric to concentric hypertrophy [196].  
 
Figure 26 - LV geometry and CV risk [196] 
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1.9.3 Pathophysiology of Left Ventricular Hypertrophy 
LVH is characterised by cardiomyocyte hypertrophy, proliferation of the extracellular 
matrix and rarefaction of the coronary micro-circulation which may ultimately cause 
ventricular dysfunction, arrhythmia and ischaemia (Figure 27)[197]. 
 
 
Figure 27- Factors involved in myocardial remodelling in HHD [198] 
 
Two patterns of hypertrophy occur, concentric and eccentric. Left ventricular mass is 
increased in both but chamber volume is reduced in the former and increased in the 
latter, expressed in the measurement of relative wall thickness (RWT) i.e. the ratio of 
the LV wall thickness to the diastolic diameter (Figure 28). Concentric hypertrophy is 
typical of conditions that increase afterload (e.g. aortic stenosis or hypertension) the 
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latter usually occurs in response to volume overload (e.g. aortic or mitral regurgitation) 
[185, 199, 200]. 
 
 
Figure 28 - Classification of LV Geometry [185] 
 
Left ventricular wall stress is inversely proportional to wall thickness in accordance 
with Laplace’s Law (Figure 29). LVH therefore compensates for an increased afterload 
by normalising wall stress to maintaining ejection fraction [199, 200]. There is evidence 
in some cases with marked hypertrophy wall stress can be sub-normal and ejection 
fraction supra-normal suggesting an exaggeration response [199]. 
 
 
Figure 29 - Laplace’s Law 
 
LV wall stress (σ) = Ventricular Pressure (P) x Radius (r)/Wall thickness (h) 
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Cardiomyocytes are terminally differentiated after birth, hence hypertrophy not 
hyperplasia of cardiomyocytes occurs [199]. This is achieved by either the parallel 
addition of sarcomeres increasing myocyte width or sarcomere replication in series 
with myocyte lengthening causing concentric or eccentric hypertrophy respectively 
(Figure 30) [199].  
 
Figure 30- Patterns of LVH and changes in the myocyte [197] 
 
Increased myosin heavy chain synthesis has been demonstrated within hours in dogs 
with acute pressure overload [201]. This contrasts with volume overload where there 
is no increase in myosin heavy chain production [201, 202] but a reduction in the 
degradation rate [202]. Apoptosis is abnormally stimulated in hypertrophied hearts 
caused by mechanical stress, humoral factors (ATII, aldosterone) and oxidative stress  
resulting in direct damage to the cell membrane, organelles and DNA shifting the 
balance towards cell death versus survival[3]. Apoptosis is an important factor in the 
evolution to decompensated heart failure in hypertensive heart disease (HHD) [203].   
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The ECM of the myocardium is primary composed of collagen type I but also contains 
elastin, laminin, fibronectin, collagen type III and V that are responsible for supporting 
the biomechanical load [199]. Unlike cardiomyocytes fibroblasts retain their mitotic 
capacity [204].  Disruption of the balance of extra-cellular matrix production and 
degradation can lead to a disproportional increase in extra-cellular volume that can 
occupy as much 30% of the myocardium [199].  Post-mortem examination of subjects 
with hypertensive heart disease found that the collagen volume fraction was 
significantly increased and proportional to the severity of the hypertrophy [205]. Pro-
fibrotic factors are thought to be triggered by defective ECM-cell contact, ischaemia or 
trophic factors such as catecholamine’s, cytokines, ATII, aldosterone and ROS [154, 
199]. Elevated procollagen type I (biomarker for type I collagen formation) and 
impaired diastolic function in mild-to-moderate hypertension and normal LVM 
suggests that fibrosis is an early feature of hypertensive heart disease [206] . 
Patients with hypertension and LVH can have signs and symptoms of myocardial 
ischaemia without obstructive coronary stenosis [207, 208]. This is due to changes in 
the vascular compartment such as perivascular fibrosis, endothelial dysfunction and a 
lower capillary/arteriolar density resulting in an impaired coronary flow reserve [209].  
Left ventricular hypertrophy develops when a there is an imbalance of hypertrophic 






Figure 31 - Hypertrophic versus anti-hypertrophic factors[197] 
 
Unlike the physiological adaptation in athletes the changes are ultimately maladaptive, 
exaggerated and result in altered perfusion, arrhythmia or ventricular dysfunction 
[102]. ROS have a role in normal cellular nitrous-redox signalling, and disruption to this 
balance is an important factor in the pathophysiology of LVH. Seddon et al proposed 
three broad pathophysiological effects of OS in the heart. Firstly direct cellular 
oxidative damage leads to dysfunction, energetic deficit and cell death, secondly 
inactivation of NO causes endothelial dysfunction and lastly activation of redox 
signalling promotes hypertrophy and fibrosis [81]. 
The primary stimulus for hypertrophy is via neurohumoral, mechanical, or a 
combination of both factors [197]. Disruption of cell to cell or cell to ECM contact is 
thought to be transmitted via focal adhesion complexes (integrins) that connect the 
cellular cytoskeleton to the ECM [199]. Released in response to pressure overload  
neurohumoral factors can act in an autocrine, paracrine or neuroendocrine fashion 
[121, 204] and include vasoactive peptides (ET-1, ATII), catecholamines, direct 
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activators of protein kinase C, peptide growth factors, cytokines and arachidonate 




Figure 32 - Stimuli of Ventricular Myocyte Hypertrophy [204] 
 
GPCR agonists activate several secondary (cytosolic) messengers that include ROS and 
mitogen-activated protein kinase (MAPK) cascades (ERKs, JNKs, p38-MAPKs) [3, 204]. 
An alternative pathway also via GPCR is calcineurin activation of NFAT (nuclear factor 
activated T lymphocytes) [204].  A number of signalling molecules have been 
proposed, but no signalling molecule has been identified as the “master switch” for the 
development of hypertrophy suggesting redundant signalling pathways are recruited 
when a single pathway is supressed [199]. 
Gene expression has been primarily linked with the expression of foetal cardiac genes 
that modify motor unit composition and function, energy metabolism and hormonal 
pathways [199]. ROS dependent activation of tertiary (nuclear) messengers that 
include nuclear factor-kappaB (NF-κB), activator protein-1 (AP-1), E26 transformation-
specific (Ets) factors have been shown to be involved in myocyte hypertrophy and ECM 
remodelling (Figure 32) and at high levels of ROS apoptosis [3, 73, 81, 210, 211]. 
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1.9.3.1 The Role of Oxidative Stress in Hypertensive LVH 
Oxidative stress is an important driver of the development of LVH and in the transition 
to decompensation (Figure 33). Figure 34 demonstrates the key REDOX sensitive 
signalling pathways and how ROS influence both adaptive and maladaptive 




Figure 33 - ROS generation and antioxidant systems in the heart[73] 
 
NADPH oxidase is a major oxidase in vascular and cardiac tissue [212] and is stimulated 
by G-protein coupled receptor (GCPR) agonists (ATII, ET-1, α-adrenergic agonists), 
cytokines (tumour necrosis factor-α) and pressure overload to generate superoxide 
[73, 211, 213]. NADPH oxidase has been demonstrated to have an important role in 
pressure overload hypertrophy [73]. NADPH oxidase can induce NOS uncoupling 
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(directly by superoxide or indirectly by the oxidation of BH4) and XO further amplifying 
ROS generation [73].  
 
 
Figure 34 - Redox-sensitive pathways in cardiomyocyte hypertrophy [211] 
 
Increased xanthine oxidase (XO) expression and activity has been demonstrated in a 
number of cardiovascular conditions including hypertension [31]. Allopurinol inhibits 
the generation of superoxide and hydrogen peroxide and has been shown to attenuate 
left ventricular remodelling animal models [73, 214, 215] and regress LVH humans [40, 
53, 59]. 
Nitric oxide (NO) causes post-translation modification of effector molecules (usually via 
S-nitrosylation) at physiological levels of superoxide which is regulated and reversible. 
NO signalling via cyclic guanosine monophosphate (cGMP) blunts cardiomyocyte 
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hypertrophy and fibrosis via transcription regulation and suppression of targeted 
signalling [73, 211]. Furthermore NO can inhibit activation of xanthine oxidase and 
NADPH oxidase to maintain superoxide/NO homeostasis [73]. When superoxide is 
abundant (e.g. pressure overload) NOS is uncoupled, peroxynitrite is formed with the 
effect of further increasing nitrosative/oxidative stress and reducing NO bioavailability 
(Figure 35) [73, 211]. Mice lacking the NOS gene had attenuated hypertrophy, dilation, 
fibrosis and ROS generation compare to wild type controls in response to transverse 
aortic constriction [90].  
 




Mitochondrial ROS have been implicated in MI and heart failure and LVH in mouse 
models [73, 211]. Monoamine oxidases (MAO) located in the mitochondria, are 
involved in oxidative deamination of catecholamines generating hydrogen peroxide, 
and has been shown to be a source of ROS in mice subjected to pressure overload 
[211]. 
ROS stimulate cardiac fibroblast proliferation and transcription factors promoting 
MMP expression in addition to post-translational MMP activation leading to fibrosis 
and matrix remodelling [73]. 
Impaired contractile function is a feature of disease progression to heart failure, an 
important component of this via redox modification of excitation/contraction coupling 
[211]. Modification of ryanodine receptor enhancing its open probability, suppression 
of L-type calcium channel current and by oxidative/nitrosative interaction with the 
sarcoplasmic reticular calcium ATPase, inhibiting calcium uptake [73, 211].  
 
1.9.4 Diagnosis 
1.9.4.1 ECG  
Numerous criteria have been developed to diagnose LVH on ECG, the first of which 
was the Sokolow-Lyon index. Developed in 1949 LVH was identified if the sum of the S 
wave in lead V1 plus the R wave in leads V5 or V6 (whichever larger) was ≥ 35mm 
[216]. Since then more than thirty criteria for the diagnosis of ECG-LVH have been 
developed and all are limited by their poor sensitivity (Sokolow-Lyon index median 
specificity 89% and sensitivity of 21%)[217]. A systematic review assessing the use of 
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multiple ECG criteria for the diagnosis of LVH concluded that the ECG should not be 
used to rule out LVH in hypertension [217].   
 
1.9.4.2 Echocardiography  
The invention of echocardiography allowed direct visualisation of the myocardium and 
development of geometric models to calculate the LVM e.g. the ASE (Figure 36) and 








Subsequent validation demonstrated very good correlation against direct left 
ventricular mass measurement post-mortem [218]. Using echo to calculate LVM has 
advantages in that there is a wealth of published data with demonstrated prognostic 
value, it is quick and widely available [1]. However, LVM mass calculations are based 
on the assumptions that the LV is of “normal” geometry (i.e. prolate ellipsoid with a 
2:1 long/short axis ratio), beam orientation is perpendicular, hypertrophy is distributed 
evenly and that good image quality is possible [1]. The standard error of estimate (SEE) 
for echocardiography is 29 – 97g (95% CI, 57 – 190g) and inter-study reproducibility is 
LV mass = 0.8 (1.04 ([LVIDD + PWTD + IVSTD]3 - [LVIDD]3))+ 0.6 g 
 
Figure 36 - ASE LV Mass Cube Formula [1] 
LV mass = 1.04 ([LVIDd + PWTd + SWTd]3 - [LVIDD]3)-13.6 g 
 




also poor (successive measurement SD 22 – 40g (95% CI, 45 – 78g)), therefore large 
numbers of patients would be required in clinical trial to assess a change in LVM to 
overcome this. Echocardiography has been found to overestimate LV mass when 
compared to CMRI, a study using both methods found the ASE echocardiographic LVM 
to be 319 +/-21g versus 232+/-11g by cardiac MRI[219]. This observation is consistent 
with findings from studies conducted at our centre [40, 41, 220]. 3D echo has been 
shown to be more accurate than linear or 2D techniques [221] and comparable to 
CMRI (Figure 38)[222] but is still dependent on image quality, which is not possible in 
around one quarter of patients screened in population studies [223]. An abnormal 
echocardiographic LVM indexed to body surface area (BSA) is currently defined as 





Figure 38- Comparison of 2D, real time 3D echo with CMRI  [222] 
 
1.9.4.3 Cardiac MRI  
Echocardiography has now been replaced by cardiac MRI as the “gold standard” for 
non-invasive measurement of LVM [224]. Accurate selection of the imaging plane, 
good tissue characterisation and consistent image quality allow accurate measurement 
of LVM independent of geometric assumptions [225].  The area between the 
epicardium and endocardium is measured on the short axis stack then multiplied by 
the inter-slice distance to calculate the volume (Figure 39). The volume is multiplied by 





Figure 39- Illustration of LVM measurement on MRI short axis [225] 
 
Gradient-echo sequences (GRE) have now been replaced by steady state free 
precession (SSFP) as the preferred technique for measurement of LVM. Both 
techniques have excellent interstudy and interobserver reproducibility [227]. SSFP 
however uses the tissue to blood T1/T2 ratio not through plane blood flow for blood-
myocardium contrast [227] and hence has better image quality parameters and 
significantly shorter acquisition times [228]. Because of differences in the sequences 
LV volumes measured by SSFP are significantly higher and LVM lower [227, 228] than 
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those calculated by GRE the normal ranges previously defined are not valid for this 
technique, see Figure 40 for SSFP normal values.  
 
 
Figure 40 - Normal LV parameters (SSFP 1.5T including papillary muscle)[229] 
 
Steady-state-free-precession (SSFP) CMR has been validated using explanted hearts at 
the time of cardiac transplant. Hearts imaged ex-vivo demonstrated a very high 
correlation to the directly measured LV mass (r=0.95, p = <0.001) [224]. Disadvantages 
of MRI are cost, suitability (i.e. metal implants/injuries etc.), tolerability or availability. 
 
1.9.5 Evidence for LVH Regression 
1.9.5.1 Pharmacological Interventions 
A meta-analysis (2003) of eighty double-blind, parallel group RCT’s included 3767 
patients looking at the effect of different antihypertensive medications on echo LVM in 
essential HTN [230]. The reduction in LVMI decreased by a mean of 13% (95% 
confidence interval [CI] 8-18%) ARB, 11% (CI 9-13%) CCA, 10% ACE-I (CI 8-12%), 8% 
diuretics (CI 5-10%), 6% BB (CI 3-8%)[230]. The reduction in LVM among classes 
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remained significant even after adjustment for diastolic BP change and treatment 
duration. A pairwise comparison (including Bonferroni correction) found ARB’s, CCB 
and ACE-I reduced the LVM more than BB (Figure 41). 
 
 
Figure 41- Meta-analysis of antihypertensive class and LV mass change [231] 
 
A more recent meta-analysis (2009) compared pooled pairwise comparisons of the 
effect on LVM of five antihypertensive drug classes from 78 studies totalling 6001 
subjects [232]. An interclass pairwise comparisons found that only ARB’s significantly 
regressed LVM more than BB, 12.5% vs 9.8% (p0.01). Multivariable meta-regression 
analysis found BB regressed LVM significantly less than the other classes [232].  
A meta-analysis of five studies with a total of 3149 patients by Pierdomenico et al 
(2010) assessed the impact on echocardiographic LVH regression on CV events in 
hypertensive patients. The risk of a CV event was 46% lower in subjects with LVH 
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regression/persistently normal LVM compared to those with LVH persistence/LVH 
development even after adjustment for confounders (HR 0.54, 95%CI 0.35-0.84, 
p0.007). There was a moderate degree of heterogeneity between the studies (I2 59%), 
a random effects meta-analysis of the variables available indicated less benefit in 
participants with a higher baseline prevalence of diabetes, CV disease and Japanese 
ethnicity. The majority of trials are in a predominantly white population and a sub 
group analysis of the CASE trial by Yasuno et al. highlighted that both ethnicity and 
comorbidities may impact on the benefit from LVH regression[233].  
 
1.9.5.2 The LIFE Study 
The Losartan Intervention for End Point Reduction in Hypertension (LIFE) was a large 
(n=9222 subjects) prospective, randomised, double blind, parallel group study 
assessing if losartan was superior to atenolol in reducing the cardiovascular morbidity 
and mortality in a hypertensive population[234]. Losartan significantly reduced the risk 
by 13% after a mean follow-up period of 4.8 years (adjusted HR 0.87, 95% CI 0.77-0.98, 
p0.021). This difference was driven by a 25% reduction in stroke (adjusted HR 0.75, 
95% CI 0.63-0.89, p0.001). There were no significant differences in BP at the end of the 
study illustrating that losartan had an effect above and beyond its effect on BP. This 
could be explained by a significant reduction of both Cornell Product (p<0.001) and 
Sokolow-Lyon Voltage (p<0.001) in the Losartan arm consistent with LVH regression. A 
Cox regression analysis was used to explore the relationship between the serum uric 
acid and the primary end-point in the LIFE study, finding that attenuation of SUA by 




A sub-study of the LIFE trial investigated the effect of LVM changes on the primary 
composite end-point in 941 subjects who had LV mass measured at enrolment then 
annually by transthoracic echo [236]. A reduction in LVM by 1SD (25.3g/m2) reduced 
the risk of CV mortality by 34% (HR 0.66, 95% CI 0.49-0.90, p0.001) and all-cause 
mortality by 26% (HR 0.74, 95%CI 0.59-0.93, p0.08) adjusted for baseline LVMI, 
treatment, BP lowering, age, smoking, diabetes, prior CVA or MI and heart failure. The 
absence versus presence of LVH corresponded to a 42% lower risk of the adjusted 
(baseline LVH, treatment, BP lowering) primary end point. Of note the decrease in 
LVMI was more marked in the highest quintiles of LVMI at baseline (p=<0.01) and the 
prevalence of LVH fell from 70% to 23% after five years. Although there was no 
difference in blood pressure between the losartan and atenolol arms it does support 
LVM regression improving outcomes. Within a sub-population (754 subjects) of the 
LIFE study changes in LVM with antihypertensive treatment was investigated with 
serial echocardiographs at baseline, 12 and 24 months [237]. A significant change in 
mean LVM from 233g at baseline to 206g at (p<0.001 adjusted for change in BP). There 
was however a smaller but significant reduction in LV mass at 24 months (195g versus 
12months p<0.001) despite no significant improvement in BP control after the first 
year. 
 
1.9.5.3 The HOPE Trial 
A sub-group analysis of the Heart Outcomes Prevention Evaluation (HOPE) trial 
assessed whether treatment with Ramipril prevented/regressed ECG-LVH in patients 
over 55 years old with cardiovascular risk factors and how a change impacted on 
prognosis [238]. Treatment with ramipril significantly reduced the 
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development/persistence of LVH compared to placebo (RR 0.83, 95% CI 0.72-0.95, 
p0.008) even after adjustment. The composite of death or the 
development/persistence of LVH again was 20% lower in the Ramipril arm (RR 0.80, 
95% CI 0.71-0.89, p<0.001) and what was striking the effect was found to be 
independent of BP. A further sub-study of the HOPE trial [84] of 506 patients with 
normal BP at baseline (~35% with hypertension) compared two doses of Ramipril 
(2.5mg and 10mg) versus placebo on echocardiographic measures of left ventricular 
mass, volumes and function. LVMI was significantly (p=0.03) reduced in the ramipril 
10mg group only (-7.21g/m2) compared to placebo even after adjustment for age, 
gender, baseline LVM, LVMI and changes in systolic and diastolic BP (p<0.05) 
supporting the findings from the sub-group analysis above. 
 
1.9.5.4 LVH Regression in Normotensive Subjects 
LVH remains prevalent even in treated hypertension. A cross sectional study by Mancia 
et al found the prevalence of LVH in those with controlled hypertension was 19% 
versus 4% in the normotensive subjects of the PAMELA cohort [177]. The blood 
pressure was significantly higher in the former subjects (128/80mmHg versus 
119/77mmHg, p<0.05) and is suggestive that conventional BP targets are not sufficient 
to completely reverse LVH. A small study by Simpson et al (2010) randomised 51 
optimally treated patients with hypertension and LVH to a stepwise escalation of 
antihypertensive medications versus placebo. For a significant mean BP change of -
9.33mmHg in the active arm versus -0.08mmHg placebo (p=0.007) there was a 
significant corresponding change in LVMI -4.68g/m2 versus +1.97 g/m2 respectively 
(p=0.014). Of note 26% withdrawal from the treatment arm with dizziness suggesting 
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tolerability could limit this strategy in practice [220]. The findings are consistent with 
the ACCORD BP trial (2015) that intensive BP therapy in a diabetic population had 39% 
lower risk of ECG-LVH (odds ratio 0.61, 95% CI 0.43-0.88, p0.008) [239]. However 
intensive BP lowering failed to reduce the combined rate of fatal and non-fatal CV 
events [240]. The SPRINT trial (2015) provided evidence for the benefit of more 
intensive BP lowering in a non-diabetic population with elevated CV risk. A mean 
systolic BP of 121.4mmHg was achieved in the intensive group versus 136.2mmHg with 
standard therapy. The intensive group had a significantly lower primary composite 
event rate 1.65% versus 2.19% (HR 0.75; 95% CI 0.64-0.89; p<0.001. Overall there was 
no significant difference in SAE between the interventions (p = 0.25) [241]. Although 
the study didn’t assess changes in LV mass it is possible that favourable LV remodelling 
was at least in part responsible to the improvements in long term outcomes. The 
reality however is that even current BP targets are not achieved by around 6% of 
patients[104]. 
 
1.9.5.5 Non-pharmacological Interventions 
Interventions of weight loss either conventionally (hypocaloric diet +/- increased 
exercise) or by bariatric surgery has evidence for LVH regression in patients with both 
normal and elevated BP[242, 243]. An important study by MacMahon et al found that 
a mean reduction of 8.3kg in weight loss was associated with a 14.8g/m2 decrease in 
LVMI (p = 0.018) and this was independent of BP change [242]. Dietary sodium 
reduction also has also been demonstrated to decrease LVH by itself or in combination 
with other lifestyle interventions [244, 245]. Current guidelines [47, 96] recommend 
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lifestyle measures in the management of hypertension however lifestyle measures in 






















2.1 Approvals and Trial Registration 
2.1.1 Ethical Approval 
The “Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated 
Essential Hypertension” (ALLAY) trial was approved by the East of Scotland Ethics 
Service (EoSRES) on the 16th June 2014, research ethics committee (REC) reference 
number 14/ES/0073. 
 
2.1.2 Medicines & Healthcare products Regulatory Agency (MHRA) 
As a clinical trial of investigational medical product (CTIMPs) using Allopurinol versus 
placebo approval was granted by the MHRA on the 24th June 2014 , EudraCT number 
2014-002083-33. 
 
2.1.3 NHS Research and Development 
Approval by the local R&D was granted after ethical and MHRA approvals were in place 
on the 6th August 2014, reference 2012CV15. 
 
2.1.4 Trial Registration 
The study was registered with ClinicalTrials.gov, reference number NCT02237339 and 





The ALLAY trial was funded by a grant from the British Heart Foundation (BHF project 
grant no. PG/13/67/30444). 
 
2.3 Study design 
The ALLAY trial is a randomised, double blind, placebo controlled single-centre study 
conducted in NHS Tayside to compare allopurinol (300mg once daily for one month, 
increased to 300mg twice daily if tolerated for a further eleven months) versus placebo 
(microcrystalline cellulose). 
 
2.4 Investigational Medical Product& Placebo 
Both placebo (microcrystalline cellulose) and allopurinol had an identical appearance 
and were manufactured by Tayside Pharmaceuticals, Ninewells Hospital, Dundee. 
Medications were stored in the Clinical Trial Pharmacy (Ninewells Hospital) and were 
dispensed on completion of the relevant forms before a study visit. An initial dose of 
allopurinol 300mg once daily was taken, increasing if tolerated to 300mg twice daily 
thereon. According the Electronic Medicines Compendium rash is the most common 
(≥1% and <10%) side effect followed by hypersensitivity, nausea, vomiting and 
abnormal LFT’s uncommonly (≥0.1% and <1%). Serious side effects such as Steven-
Johnson syndrome, toxic epidermal necrolysis or hepatitis occur rarely (≥0.01% and 
<0.1%). Allopurinol must be used with care in patients with liver or renal dysfunction 
as this increases the risk of side effects. 
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2.5 Study Aims 
We hypothesised that the inhibition of xanthine oxidase using allopurinol would 
regress LVM by reducing oxidative stress in patients with optimally treated, well 
controlled essential hypertension.  
 
2.5.1 Primary endpoint 
To determine if allopurinol induces a change in Left Ventricular Mass Index in patients 
with treated hypertension when compared to placebo, measured by cardiac MRI. 
 
2.5.2 Secondary endpoints 
To assess the effect of Allopurinol on; 
• Endothelial function as measured by FMD and vascular stiffness measured by 
PWA and PWV 
• Blood Pressure 
• Urate, High sensitivity C-Reactive Protein (HsCRP), Thiobarbituric acid reactive 
substances (TBARs), N-terminal prohormone B-Type Natriuretic Peptide (NT-
proBNP), Procollagen type I carboxy-terminal Propeptide (PICP) and soluble ST2 
(sST2). 
• Changes to absolute LV mass, LV end-systolic volume, end-diastolic volume and 
ejection factor. 
• Cardiac muscle regression independent of scar tissue using gadolinium 
enhancement. 
• Change in LA volumes 
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2.6 Inclusions Criteria 
Participants were eligible if they fulfilled the criteria below; 
• are aged over 18 years  
• previously diagnosed with essential hypertension 
• been on stable antihypertensive therapy for at least 3 months prior to study 
screening  
• have screening ABPM (or home-based BP monitoring if ABPM not tolerated) 
with daytime average systolic <135mmHg or 24-hour average systolic ≤ 
130mmHg 
• have screening echocardiography-based diagnosis of LVH based on ASE criteria 
(males >115g/m2, females >95g/m2)  
 
2.7 Exclusion Criteria 
Subjects were excluded if they had any of the following; 
• documented intolerance to allopurinol  
• left ventricular ejection fraction <45% on echocardiography screening 
• severe aortic stenosis on echocardiography screening  
• active gout (i.e. gout flare <2yrs) or currently on allopurinol  
• severe hepatic disease  
• renal disease; CKD class 3B or worse 
• on azathioprine, 6 mercaptopurine, or theophylline 
• malignancy (receiving active treatment) or other life-threatening diseases  
• pregnant or lactating women  
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• any contraindication to MRI (claustrophobia, metal implants, penetrative eye 
injury or exposure to metal fragments in eye requiring medical attention) 
• patients who have participated in any other clinical trial of an investigational 
medicinal product within the previous 30 days will be excluded 
• patients who are unable to give informed consent 
• any other considered by a study physician to be inappropriate for inclusion 
 
2.8 Randomisation 
After confirmation of eligibility participants were randomised by the research fellow 
(CG) to allopurinol or placebo in a double-blind fashion. Randomisation used a web-
based good clinical practice (GCP) compliant randomisation system, run by the United 
Kingdom Clinical Research Network (UKCRN) registered Tayside Clinical Trials Unit 
(TCTU). Randomisation was minimised for sex and left ventricular mass index (LVMI) 
i.e. males LVMI >115g/m2 to <130g/m2 or ≥130g/m2, females >95g/m2 to <115g/m2 or 
≥115g/m2. Double blind medication (allopurinol/placebo) was prepared, packaged and 
labelled by Tayside Pharmaceuticals. Medication will come labelled as “Pack No. 001”, 
“Pack No. 002”, etc. Blinding was maintained until all analysis, data entry/validation 
was completed, and the data was locked.   
 
2.9 Recruitment 
Study subjects were recruited from the following sources; 
• NHS Tayside Cardiovascular Risk or Cardiology Clinics 
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• Previous participants of clinical trials in Cardiology at NHS Tayside and/or in the 
University of Dundee Department of Clinical Pharmacology 
• Local clinical echocardiography databases in NHS Tayside 
• Scottish Primary Care Research Network (SPCRN) 
• Scottish Health Research Register (SHARE) 
 
2.9.1 Informed consent 
All subjects were sent the full participant information sheet a minimum of twenty-four 
hours before attending for the screening visit. When consent was taken first the trial 
was explained, risks and benefits discussed, the consent form read and explained 
follow by an opportunity to ask questions and have them answered before signing 
(appendix chapter 9.4). Tests of endothelial function (PWA/PWV/FMD), research and 
genetic bloods could be opted out of.  
 
2.10 Study Visits 
Participants had a total seven study visits over a period of twelve to thirteen months 
described in detail below. Participants continued their usual medications. For a 
summary table of the visit schedule see appendix (chapter 9.3). 
 
2.10.1 Screening Visit (Visit 1) 
• Participant consent  
• Height, weight measured 
• Screening echocardiogram 
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• Inclusion/exclusion criteria 
• Medical, drug, social and family history were recorded followed by physical 
examination 
• Vital signs (i.e. office BP, pulse) 
• Safety/baseline bloods 
• 24-hour ambulatory BP or home BP monitoring  
 
2.10.2 Randomisation (Visit 2) 
• Adverse event (AE) log completed 
• Concurrent medication log updated 
• Vital signs 
• Electrocardiograph (ECG)  
• Pulse wave velocity (PWV)/Pulse wave analysis (PWA) 
• Flow medicated dilatation (FMD) 
• Cardiac Magnetic Resonance Imaging (CMRI)  
• Research, genetic bloods and blinded uric acid 
• Randomisation 
• Study medications supplied and first dose (300mg allopurinol/placebo) taken 
 
2.10.3 Progress Visits (Visits 3, 4, 5 and 6) 
• Adverse event log completed 
• Concurrent medication log updated 
• Vital signs 
• Medication compliance Log 
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• Safety bloods and uric acid 
• Urine pregnancy test (if applicable) 
• Study medication supplied 
 
2.10.4 Final Visit (Visit 7) 
• Adverse event log completed 
• Concurrent medication log updated 
• Vital signs 
• Medication compliance Log 
• ECG  
• PWV/PWA  
• FMD  
• CMRI  
• Safety, research, genetic bloods and blinded uric acid 
• 24-hour ambulatory BP or home BP monitoring  
• Completion of study form 
 
2.11 Blood Pressure Monitoring 
Sitting upright after resting for a minimum of five minutes the office BP was recorded 
using a calibrated Omron 705IT (Omron Healthcare co LTD, Kyoto, Japan). Ambulatory 
BP monitoring was taken at visit 2 and 7 using a calibrated Spacelabs 90217A 
(Spacelabs Healthcare, Hertford, United Kingdom) or home BP using the Omron 705IT. 
The same arm and cuff size appropriate for the patient was used. 
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2.12 Applanation Tonometry 
Augmentation index (AIx) and pulse wave velocity (PWV) was performed at visits 1 and 
7 by a blinded single trained operator (CG) using a validated SphygmoCor system 
(AtCor, Sydney, Australia) and a high fidelity micromanometer. The participant was 
rested for at least five minutes in a supine position before measurements were taken. 
For AIx the micromanometer was applied to the distal radial artery to obtain a 
peripheral pressure waveform. Recordings were made until consistent measurements 
(minimum of two) were achieved with a minimum operator index (>70). The recording 
with the highest operator index and most consistent waveform was selected. 
Augmentation index is calculated by the increment in pressure from the systolic 
shoulder as a percentage of the peak pulse pressure (Figure 42) [246] and was 
generated automatically by the software (Figure 43).  
 
 






Figure 43 - Pulse Wave Analysis (Own Image) 
 
To calculate PWV, radial-carotid waveforms were obtained with simultaneous ECG 
gating. Velocity was calculated by the software using the manually measured distance 
(sternal notch to selected point of carotid pulsation and sternal notch to distal radial 
pulsation) and time interval from the ECG R-wave and the start of the pressure 
waveform. Recordings were made (minimum of two) until a consistent PWV result was 
obtained of sufficient quality. The PWV with the lowest SD and best waveform was 
selected (Figure 45). Carotid-femoral PWV is the “gold” standard for measuring large 





Figure 44 - Pulse Wave Velocity (own image) 
 
2.13 Flow Mediated Dilatation (FMD) 
FMD was conducted as per the international brachial artery reactivity task force 
guidelines [249] at visits 1 and 7 to measure endothelial dependent (hyperaemia) and 
independent vasodilation (GTN). Brachial FMD was conducted by a blinded single 
trained operator (CG) using an Acuson Sequoia 512 (Siemens, Camberley, UK) with an 
8MHz linear array probe and simultaneous ECG gating.  
With the subject rested supine for a minimum of five minutes the brachial artery was 
imaged in the longitudinal plane above the elbow with the probe mechanically fixed in 
place when an adequate view of the vessel intima and lumen was acquired, altering 2d 





Figure 45 - Flow Mediated Dilation Procedure [250] 
 
 
A resting 2d recording of the artery was acquired for one minute. Ischaemia was 
induced with a blood pressure (BP) cuff inflated around the forearm at 50mmHg above 
systolic pressure or 200mmHg which ever was highest. After five minutes the cuff was 
rapidly deflated followed by a 2d recording for two minutes. The participant rested the 
arm for ten minutes and a repeat baseline image was recorded for one minute. 
Endothelium independent dilation was assessed by giving 400mcg glyceryl trinitrate 
sub-lingually and the final recording was started after two minutes recording for a total 
of five minutes. 
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The FMD was analyzed by a blinded single trained operator (CG) using the Vascular 
Research Tools software (Medical Imaging Applications LLC, Coralville, IA, USA) to track 




Figure 46- FMD Analysis (own image) 
 
2.14 Echocardiography 
Using the joint American Society of Echocardiography and European Association of 
Cardiovascular Imaging guidelines [1]. Perpendicular 2D guided measurements of the 
intra-ventricular septum, internal diameter and posterior wall of the LV were acquired 
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in the parasternal long axis, at the level of the mitral valve leaflets tips at end-diastole 
by a single operator (CG). LV mass was calculated using the ASE mass cube formula[1]. 
A Phillips IE33 (Phillips Healthcare, Amsterdam, Netherlands) was used until it was 
replaced on the 10th of November 2015 with a Phillips EPIQ (Phillips Healthcare, 
Amsterdam, Netherlands). 
 
2.15 Cardiac MRI 
Cardiac MRI was performed on a 3T MAGENTOM Trio-PrismaFIT (Siemens, Erlangen, 
Germany) using dedicated phased array cardiac coils. Serial contiguous short-axis cine 
images (electrocardiogram gated, [true fast imaging with steady-state precession 
(TrueFISP)] were acquired from the AV ring to the apex using the vertical and 
horizontal long axis of the left ventricle as a guide. The short axis imaging parameters 
were repetition time (TR) of 2.5ms, echo time (TE) of 1.1ms, flip angle (FA) of 60°, and 
slice thickness 6mm and 4mm gap. 
Late gadolinium enhancement images were acquired approximately 10-15 minutes 
after the initial bolus injection of contrast agent (DotaremTM, Guerbet, France).  At 10 
minutes post-injection, a 2D segmented CINE TrueFISP 'TI scout' sequence (with 
prospective gating) was applied at a single slice location in the mid-short axis plane in 
order to identify the correct inversion time (TI) to null the signal from healthy 
myocardium.  The TI scout sequence works by acquiring a selection of images with 
different TI times, and the scanner operator can then select the TI time that 
corresponds to the image where the healthy myocardium signal is the lowest.  For the 
TI scout sequence the imaging parameters were TR/TE = 3.13/1.39 ms, flip angle 35o, 
8mm slice thickness, field of view 340-380mm and bandwidth 965 Hz/pixel. 
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After the correct TI had been established, the LGE images were acquired using a 2D 
ECG prospective gated single-shot segmented phase sensitive inversion recovery (PSIR) 
TrueFISP sequence.  Typically, 10 slices (each 8mm thick) were acquired in the short 
axis plane (from base to apex) over a field of view of 340-380 mm with in-plane matrix 
of 192x192 pixels.  The TR/TE was 2.55/1.10 ms, with flip angle 40o, parallel imaging 
(iPAT) factor 2, and bandwidth 1532 Hz/pixel. 
Analysis was performed offline by a single trained observer (CG) blinded to the study 
allocation using Argus software (Version VB15, Siemens Erlangen, Germany). Using the 
short axis stack ‘region-of-interest’ contours were placed around the left ventricular 
endocardial and epicardial borders at end diastole and at end systole to calculate left 
ventricle ejection fraction (LVEF), left ventricular mass (LVM), end-diastolic (LVEDV), 
end-systolic (LVESV) and stroke volumes (LVSV). The base and apex were labeled and 
frames with ≥50% full thickness myocardium were included in the LVM. Papillary 
muscles were also included in the LVM if the muscle was contiguous with the 
myocardial wall. Each scan was analyzed twice to ensure consistency, a third 
measurement was conducted if the LVM varied by >5%. 
‘Region of interest’ contours were placed around the blood pool in left atria (LA) 
during diastole and systole excluding the LA appendage and pulmonary veins where 
possible. From these measurements the LA end diastolic volume (LAEDV), end systolic 
volume (LAESV), stroke volume (LASV) and ejection fraction (LAEF) could be calculated. 
Images were screened for LGE using Argus software, any positive or suspected of 
having LGE were reviewed for inclusion/exclusion by a radiologist (GH) and then 
analyzed using Circle (Circle Cardiovascular Imaging inc, Calgary, Alberta, 
Canada).‘Region of interest’ contours were placed on each of the slices from the short 
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axis stack to exclude high signal outside the myocardium, areas of enhancement not 
caused by scar were excluded manually, the software automatically calculated the 
volume of LGE. LGE positive was defined as cases with a signal intensity above the 
average of the normal myocardium plus 3 standard deviations.  
 
2.16 Studies of Agreement 
A single observer who was blinded to treatment allocation (CG) analysed the CMRI. 
Intra-observer measurement of LVM had an interclass correlation coefficient of 0.999 
(95% CI 0.998 – 0.999; p = <0.0001). Figure 47 shows a Bland Altman plot of LVM 
measurements.   
 
 
Figure 47 – Bland Altman plot of CMRI LVM Measurement 
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Middle line mean difference, upper and lower lines mean ± 2SD 
Intra-observer measurement of FMD interclass correlation coefficient was 0.813 (95% 
0.435 – 0.938; p = 0.002). Intra-observer measurement of AIx interclass correlation 
coefficient was 0.995 (95% 0.989 – 0.998; p <0.001). Intra-observer measurement of 
PWV interclass correlation coefficient was 0.860 (0.691 – 0.937; p <0.001). 
 
2.17 Laboratory tests 
2.17.1 Biochemistry &Haematology 
Urea and electrolytes, liver function tests, lipids, glucose, HBA1c (subjects with 
diabetes), full blood count and urate were taken with vacutainer tubes and taken 
immediately for processing in the NHS Tayside laboratory.  
 
2.17.2 Biomarkers 
Approximately 10mls of blood was collected in two gold top bottles (SST II advance) 
and allowed to clot at room temperature for 15 minutes, then spun at 3000rpm at 4oc 
for ten minutes. Serum was removed and placed in x4 1ml labelled plastic tubes for 
storage at -20oc and -70oc. A further 4ml sample was taken in a purple top (EDTA) 
bottle and stored in a -20oc freezer.  
 
2.17.2.1 Uric Acid 
Samples were collected in a gold top (SST II advance) tube and processed in the NHS 
Tayside biochemistry lab throughout the trial using Siemens ADVIA chemistry systems 
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using the Fossati enzymatic reaction method. The results were not available until the 
end of the study to preserve the integrity of the blind.  
 
2.17.2.2 Thiobarbituric acid reactive substances  
Lipid peroxidation results in a number of intermediate or end products that includes 
malondialdehyde (MDA) [251]. Thiobarbituric acid reacts with oxidised lipids including 
the major lipid oxidation product MDA to form thiobarbituric acid reactive substances 
that are measured by the TBAR assay and hence quantify the degree of lipid 
peroxidation [251]. There is  strong positive correlation between plasma MDA and 
TBARS concentration (r = 0.709) [251]. Serum levels of TBARs have been shown to be 
strongly, and independently predictive of cardiovascular events in healthy patients and 
those with stable coronary disease [252, 253]. Other biomarkers for oxidative stress in 
cardiovascular disease such as F2-isoprostanes are considered the more reliable in-vivo 
marker of OS, however analysis is labour-intensive, expensive and therefore not 
practical for this study  [254]. Other promising markers of OS are nuclear factor 
erythroid 2-related factor 2 (Nrf2) that regulate expression of anti-oxidant defences 
and show promise in cardiovascular disease [255].  
 
 
2.18 Data entry and Management 
Data was collected on a case report form (CRF) (appendix 9.5) and transcribed to a GCP 
compliant excel database according to TASC SOP48 and stored on a password 
protected device. Data validation used single entry (CG) with a second individual 
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reading aloud whilst the data recorded is checked (CG/RS). All data analysis and entry 
took place before the database was locked (27th September 2017) according to TASC 
SOP DOM32 at which time unblinding took place.  
 
2.19 Cohort size & power calculation 
For the primary end-point, the study was powered for an absolute change in the in left 
ventricular mass on cardiac MRI based on previous studies conducted in our 
department. In those studies (LVH regression using allopurinol in patients with 
ischemic heart disease) they found that allopurinol significantly reduced LV mass by -
5.2± 5.8 grams compared to placebo -1.3±4.5 grams (p<0.007) [59].  
For an 80% power at a 5% significance level (p=0.05), to detect a similar change in LV 
mass, will require 29 subjects per group. Both our previous studies have shown a 10% 
drop-out rate. Therefore, accounting for this, a total of 64 patients (32 per group) were 
required. 
The minimum statistically significant improvement that can be detected with 
intervention is 2% [249]. Based on previous studies we would need 27 participants per 
arm to detect a 2% change with 80% power at the p<0.05 level, assuming a SD of 2.6. 
Allowing for 20% dropout we plan to randomise a total of 66 patients. 
 
2.20 Statistical analysis 
Descriptive statistics are expressed in the form of means and standard deviations for 
normally distributed continuous variables, non-normally distributed data are 
presented as median and inter-quartile ranges. Percentages and denominators were 
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used for categorical variables. Statistical analysis was undertaken using SPSS version 
22.0 (SPSS, Chicago, IL). A p value of <0.05 was considered statistically significant. 
For the primary analysis a comparison between arms of the trial was assessed by the 
regression coefficient for treatment arm with final visit LV Mass Index as dependent 
variable and gender, baseline LV mass Index and blood pressure as covariates in a 
general linear regression model. The dependent variable will be assessed for 
approximation to a normal distribution and transformed if necessary. A secondary 
analysis of the primary end-point used a mixed model to account for missing data was 
conducted.  
Comparison of baseline characteristics, all secondary end-points and sub-group 
analyses used a student t-test (normally distributed continuous variables) or the 
Mann-Whitney U test (non-normally distributed continuous variables). Categorical 
variables were analysed using χ2 test.  
 
2.21 Adverse events 
Adverse events reporting was carried out in accordance with TASC SOP 11 (identifying, 
recording and reporting adverse events for clinical trials of investigational medical 
products). All reported AE’s will be recorded on the AE page of the CRF. The 
appropriate investigation, treatment, referral of follow-up will be determined by the 
investigator. Serious adverse events (SAE), serious adverse reactions (SAR) and 
suspected unexpected serious adverse reaction (SUSAR) were reported to TASC 
pharmacovigilance section within twenty-four hours. AEs were coded according to the 
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medical dictionary for regulatory activities (MedDRA) version 20.0 by preferred term 
(PT) and system organ class (SOC).  
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected unexpected 
serious adverse reaction (SUSAR) is defined as one that: 
• results in death 
• is life threatening  
• requires hospitalisation or prolongation of existing hospitalisation 
• results in persistent or significant disability or incapacity 
• is a congenital anomaly or birth defect 














3.1 Screened Subjects 
Of a total of 272 participants who were screened, 200 were excluded for the following 
reasons: 
• No LVH on echocardiography (n=123) 
• Uncontrolled hypertension (n=53) 
• Insufficient echo quality (n=7) 
• Contraindications to MRI (n=7) 
o Previous metal penetrating eye injury (n=4) 
o Claustrophobia (n=3) 
• Other (n=10) 
o Gout (n=3) 
o Not hypertensive (n=1) 
o Change in BP medications <3 months (n=1) 
o Severe aortic stenosis (n=1) 
o Taking theophylline (n=1) 
o Active cancer treatment (n=1) 
o Atrial fibrillation (n=1) 
o Decided not to take part (n=1) 
 
3.2 Randomized Subjects 
72 participants were randomized, the original target was exceeded as time and the 
protocol allowed the replacement of subjects who withdrew from the study. 10 
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participants withdrew from the study, 6 from the placebo group, 4 from the allopurinol 
group. The breakdown of recruitment is demonstrated in the consort diagram (Figure 
48). Adverse events are discussed further in chapter 3.12, including those in the 

















Figure 48 - CONSORT diagram of Study Recruitment 
Total Screened (n=272) 
Not Recruited (n=200) 
No LVH (n=123) 
Uncontrolled hypertension (n=54) 
Inadequate echo (n=7) 






Randomised to Placebo   
(n=36) 
Randomised to Allopurinol 
(n=36) 
Withdrawals (n=4) 
Side Effects (n=3) 
Patient Choice (n=1) 
 
Withdrawals (n=6) 
Side Effects (n=6) 
 
Completed Trial (n=30) 
 
Completed Trial (n=32) 
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3.3 Baseline characteristics 
The baseline characteristics of the recruited patient are demonstrated in (Table 2) 
There was no significant difference between the groups at baseline, importantly there 
were no statistically significant differences in gender, BMI, blood pressure, number of 
antihypertensive medications, urate and LV mass. The average duration since diagnosis 
of hypertension was 12 years prior to entry into the trial. The majority of patients had 
24hour ambulatory BP monitoring, although 19% had home BP monitoring there were 
no significant differences between the groups (see Table 4 for a detailed breakdown of 
baseline BP).  
 
Table 2 - Baseline Characteristics 
Variable All Patients Placebo Allopurinol p value 
Total Patients n =72 n = 36 n = 36  
     
Mean Age (years) 66.2 ± 9.9 65.6 ± 10.4 66.8 ± 9.4 0.611 
Male 40 (55.6%) 20 (55.6%) 20 (55.6%) 1.000 
BMI  30.6 ± 5.2 30.9 ± 5.1 30.4 ± 5.3 0.686 
     
Daytime SBP  
AMBP or home monitoring 
(mmHg) 
124.9 ± 8.1 125.6 ± 7.4 124.3 ±8.8 0.557 
Daytime DBP  
AMBP or home monitoring 
(mmHg) 
73.7 ± 8.5 74.5 ± 7.2 72.9 ± 9.6 0.439 
     
Duration of HTN (years) 12.3 ± 8.4 12.4 ± 9.5 12.1 ± 7.3 0.868 
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IHD 2 (2.8%) 0 (0%) 2 (5.6%) 0.493 
Dyslipidaemia 29 (40.3%) 14 (38.9%) 15 (41.7%) 0.810 
CVA/TIA 8 (11.1%) 4 (11.1%) 4 (11.1%) 1.000 
DM 4 (5.6%) 3 (8.3%) 1 (2.8%) 0.614 
PAD 1 (1.4%) 1 (2.8%) 0 (0%) 1.000 
     
Smoker 4 (5.6%) 3 (8.3%) 1 (2.8%)  
0.567 Ex-smoker 30 (41.7%) 14 (38.9%) 16 (44.4%) 
Never Smoked 38 (52.8) 19 (52.8%) 19 (52.8%) 
     
ACE-I 32 (44.4%) 18 (50.0%) 14 (38.9%) 0.343 
Β blocker 21 (29.2%) 8 (22.2%) 13 (36.1%) 0.195 
CCB 48 (66.7%) 26 (72.2%) 22 (61.1%) 0.317 
α blocker 16 (22.2%) 7 (19.4%) 9 (25.0%) 0.571 
Thiazide diuretic 27 (37.5%) 16 (44.4%) 11 (30.6%) 0.224 
Loop diuretic 6 (8.3%) 4 (11.1%) 2 (5.6%) 0.674 
MRA 5 (6.9%) 3 (8.3%) 2 (5.6%) 1.000 
ARB 29 (40.3) 12 (33.3%) 17 (47.2%) 0.230 
Centrally acting anti-
hypertensive 
2 (2.8%) 1 (2.8%) 1 (2.8%) 1.000 
Renin Blocker 1 (1.4%) 1 (2.8%) 0 (%) 1.000 
Number of Antihypertensive 
Medications 
2.6 ± 1.2 2.7 ± 1.1 2.5 ±1.3 0.622 
Resistant Hypertension 15 (20.8) 7 (19.4) 8 (22.2) 0.772 
     
Haemoglobin (g/L) 139.3 ± 13.0 138.9 ± 12.2 139.75 ± 14.0 0.788 
Creatinine (mmol/L) 70.6 ± 13.7 73.7 ± 10.8 67.5 ± 15.7 0.058 
Glucose (mmol/L) 5.58 ± 0.90 5.39 ± 0.81 5.77 ± 0.95 0.072 
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Urate (µmol/L) 360.8 ± 97.9 374.31 ± 85.63 347.28 ± 108.33 0.244 
HS-CRP (mg/L) 2.24 ± 3.13 2.34 ± 3.40 2.14 ± 2.88 0.795 
TBARs (uM) 2.91 ± 0.95 3.01 ± 1.01 2.81 ± 0.88 0.396 
NTproBNP (ρg/mL) 775.97 ± 889.73 657.59 ± 696.49 897.73 ± 1048.96 0.258 
PICP (ng/L) 1.62 ± 0.85 1.74 ± 0.99 1.50 ± 0.70 0.269 
Soluble ST2 (ng/mL) 19.66 ± 9.42 19.56 ± 7.76 19.76 ± 10.98 0.932 
     
Echo LVM (g) 244.9 ± 57.7 245.0 ± 59.0 244.7 ± 57.2 0.979 
Echo LVMI (g/m2) 124.0 ± 18.3 124.7 ± 20.4 123.3 ± 16.3 0.751 
     
MRI LVM (g) 128.21 ± 37.39 130.56 ±36.26 125.86 ± 38.86 0.597 
MRI LVM Height1.7(g/m1.7) 52.5 ± 11.9 53.9 ± 11.9 51.0 ± 11.8 0.288 
MRI LVMI (g/m2) 64.78 ± 14.17 66.43 ± 14.71 63.13 ± 13.61 0.327 
MRI LVEDV (mL) 141.56 ± 33.62 142.16 ± 35.82 140.97 ± 31.77 0.882 
MRI LVESV (mL) 36.82 ± 15.49 36.94 ± 17.60 36.71 ± 13.29 0.951 
MRI LVSV (mL) 104.74 ± 21.80 105.22 ± 22.08 104.26 ± 21.82 0.853 
MRI LV Ejection Fraction (%) 74.7 ± 6.3 75.0 ± 7.0 74.5 ± 5.6 0.732 
     
MRI LAEDV (ml) 89.6 ± 23.8 88.6 ± 25.3 90.7 ± 22.4 0.719 
MRI LAESV (ml) 42.0 ± 15.8 40.7 ± 15.2 43.4 ± 16.5 0.493 
MRI LA Ejection Fraction (%) 54.0 ± 7.3 54.7 ± 6.1 53.2 ± 8.4 0.415 
     
FMD (%) 
Endothelial Dependent 
5.6 ± 4.0 5.4 ± 4.4 5.9 ± 3.7 0.594 
FMD (%) 
Endothelial Independent 
15.5 ± 6.0 15.1 ± 5.2 15.9 ± 6.9 0.593 
AIx (%) 22.6 ± 14.0 20.4 ± 13.7 24.8 ± 14.2 0.183 




Table 3 - Baseline MRI LVM/LVMI by gender 
Variable All Patients Placebo Allopurinol P value 
Male MRI LVM (g) 152.1 ± 31.6 152.7 ± 31.9 151.5 ± 32.2 0.905 
Female MRI LVM (g) 98.3 ± 17.0 102.9 ± 17.6 93.8 ± 15.5 0.132 
     
Male MRI LVMI (g/m1.7) 58.1 ± 11.9 59.2 ± 12.4 57.9 ± 11.6 0.538 
Female MRI LVMI (g/m1.7) 45.5 ± 7.4 47.4 ± 7.4 43.6 ± 7.0 0.148 
 
 
Table 4 – Detailed Breakdown of baseline BP 







 n = 14 n = 4 n = 10  
Daytime Home SBP 
 (mmHg) 
128.6 ± 4.4 130.8 ± 2.6 127.7 ± 4.8 0.261 
Daytime Home DBP  
(mmHg) 
75.3 ± 8.7 77.0 ± 7.3 74.6 ± 9.4 0.658 
 n = 58 n = 32 n = 26  
Daytime Ambulatory SBP 
(mmHg) 
124.1 ± 8.5 124.9 ± 7.5 123.0 ± 9.6 0.384 
Daytime Ambulatory DBP 
(mmHg) 
73.3 ± 8.4 74.2 ± 7.2 72.3 ± 9.8 0.402 
 n = 57 n = 31 n = 26  
24hour Ambulatory SBP 
(mmHg) 
121.1 ± 8.4 121.6 ± 7.6 120.5 ± 9.4 0.635 
24hour Ambulatory DBP 
(mmHg) 





3.4 Effect of Allopurinol on CMRI Parameters 
The primary finding of the study was that allopurinol attenuated LVM regression 
compared to placebo. Those taking allopurinol were found to have a significantly 
higher final indexed (height1.7) and absolute LVM than those taking placebo, after 
correction for gender, baseline systolic BP and baseline LVM (Table 5).                   
A large percentage of subjects (14%) withdrew during the study so a secondary 
analysis of the primary end-point was performed using a mixed model that confirmed 
the finding from the primary analysis (β 1.49, 95% CI 0.43 – 2.66, p = 0.007). The 
scatter graph in Figure 49 and Figure 50 shows the change in LVM/LVMI per subject in 
those in each arm of the trial.  
 
Table 5 - Multiple regression (Adjusted*) 
Dependent 
Variable 







1.36 0.38 2.34 0.007 0.975 
Absolute LVM (g) 3.43 0.91 5.95 0.008 0.983 
 
*Gender, baseline systolic BP, baseline LVMI/LVM 


























P = 0.008 
Figure 49 - Change in LVMI height1.7 according to study allocation. 
Horizontal line indicated mean 
 
P = 0.012 
Figure 50 - Change in absolute LVM according to study allocation                       




There was no significant change in other LV or LA parameters measured by CMRI 
(Table 6, Table 7). Changes in weight can affect the LVM independently of the BP, 
however there was no significant difference between arms of the trial (placebo -1.61 ± 
4.79kg versus allopurinol -0.72 ±3.05kg; p = 0.386). 
 




n = 30  
Allopurinol 
n = 32 
p Value 
Baseline Indexed LVM (g/m1.7) 54.28 ± 11.87 52.19 ± 11.74 0.489 
Final Indexed LVM (g/m1.7) 52.68 ± 11.73 52.00 ± 11.77 0.823 
Change Indexed LVM (g/m1.7) -1.60 ± 1.60 -0.18 ± 2.39 0.009 
Baseline Absolute LVM (g) 132.50 ± 35.24 130.26 ± 38.51 0.812 
Final Absolute LVM (g) 128.76 ± 35.33 129.89 ± 39.01 0.906 
Change Absolute LVM (g) -3.75 ± 3.89 -0.37 ± 6.08 0.012 
Baseline EDV (ml) 142.48 ± 38.03 144.55 ± 31.17 0.815 
Final EDV (ml) 144.80 ± 34.93 151.02 ± 38.84 0.511 
Change EDV (ml) 2.32 ± 18.26 6.47 ± 16.35 0.349 
Baseline ESV (ml) 36.57 ± 18.91 37.29 ± 13.27 0.862 
Final ESV (ml) 35.55 ± 17.13 38.87 ± 16.85 0.444 
Change ESV (ml) -1.02 ± 10.64 1.59 ± 10.28 0.331 
Baseline SV (ml) 105.91 ± 22.56 107.27 ± 20.94 0.807 
Final SV (ml) 109.25 ± 22.42 112.15 ± 25.92 0.641 
Change SV (ml) 3.34 ± 10.90 4.88 ± 10.84 0.579 
Baseline EF (%) 75.54 ± 7.19 74.73 ± 4.91 0.604 
Final EF (%) 76.57 ± 7.67 74.98 ± 6.44 0.379 












LAEDV (ml) 3.81 ± 8.86 2.57 ± 8.68 0.605 
LAESV (ml) 2.88 ±5.04 2.32 ± 6.78 0.730 
LASV (ml) 0.93 ± 6.82 0.26 ± 8.23 0.746 
LAEF (%) -1.36 ± 4.93 -1.07 ± 5.88 0.849 
 
A sub-group analysis by baseline tertile of LVM/LVMI didn’t reveal a clear pattern to 
suggest an effect with low/high baseline LVM (Table 8). A further analysis excluding 
subjects with diabetes, ischaemic heart disease, cerebrovascular or peripheral vascular 
disease was consistent with the primary analysis (Table 9). Females had a significant 
reduction in LVM compared to placebo, in males the vector of change was the same 
but of a smaller magnitude that failed to reach statistical significance (Table 10). 
 
Table 8 - Change in LVM(I) according to baseline LVM(I) tertile 













































Table 9 - Multiple regression (adjusted) excluding those with comorbidities* 
Dependent Variable β 95% Confidence Interval p 
Lower Bound Upper Bound 
LVMI (g/m1.7) 1.04 0.01 2.06 0.047 
 
*IHD, CVA/TIA, PVD and DM 
 Positive indicates an increased value in the allopurinol cohort 
 
 
Table 10 - Effect of Allopurinol on MRI Parameters by Gender 
Variable 
 
Placebo Allopurinol p Value 
 
Male Absolute LVM  
(g) 
-2.98 ± 4.24 -0.25 ± 6.8 0.152 
Female Absolute LVM 
(g) 
-4.89 ± 3.11 -0.57 ± 4.86 0.016 
Male Indexed LVM 
 (g/m1.7) 
-1.21 ± 1.69 -0.14 ± 2.55 0.141 
Female Indexed LVM  
(g/m1.7) 











Table 11 - Change in LVM(I) according to baseline urate tertile 










































Table 12 - Change in LVM(I) according to baseline TBARs tertile 
 1st Tertile  2nd Tertile 3rd Tertile 

































3.5 Effect of Allopurinol on Blood Pressure 
No significant change in blood pressure was found in the study. Although most 
subjects had twenty-four-hour ambulatory blood pressure monitoring, approximately 
one fifth had home blood pressure monitoring. No significant difference was found 





Table 13 - Effect of Allopurinol on Blood Pressure 
Variable 
 
Placebo Allopurinol p Value 
 n = 30 n = 32  
Daytime SBP  
AMBP or home monitoring 
(mmHg) 
1.6 ± 7.3 -0.9 ± 8.0 0.205 
Daytime DBP  
AMBP or home monitoring 
(mmHg) 
0.1 ± 5.4 0.3 ± 5.7 0.846 
 n = 4 n = 9  
Daytime Home SBP 
 (mmHg) 
1.5 ± 7.4 -3.4 ± 6.6 0.252 
Daytime Home DBP  
(mmHg) 
1.0 ± 5.0 0.4 ± 6.8 0.887 
 n = 25 n = 23  
Daytime Ambulatory SBP 
(mmHg) 
1.4 ± 7.6 0.0 ± 8.5 0.549 
Daytime Ambulatory DBP 
(mmHg) 
0.1 ± 5.6 0.3 ± 5.4 0.908 
 n = 24 n = 23  
24hr Ambulatory SBP  
(mmHg) 
1.2 ± 8.0 0.6 ± 8.0 0.799 
24hr Ambulatory DBP 
(mmHg) 





3.6 Effect of Allopurinol on Endothelial Function 
No significant difference was detected in endothelial function measured by flow 
mediated dilation Table 14. 
 
3.7 Effect of Allopurinol on Vascular Stiffness 
No significant difference was detected in either augmentation index or pulse wave 
velocity Table 14. Additionally, there was no correlation between the vascular markers 
before or after treatment.  
 
Table 14 – Effect of Allopurinol Endothelial Function and Vascular Stiffness 
Variable 
 
Placebo Allopurinol p Value 
FMD (%) 
Endothelial Dependent 
-0.23 ± 3.65 0.14 ± 4.12 0.718 
FMD (%) 
Endothelial Independent 
1.07 ± 4.23 0.28 ± 6.51 0.581 
AIx (%) 
 
-0.30 ± 13.46 0.06 ± 12.41 0.913 
PWV (m/s) 
 





3.8 Effect of Allopurinol on Biomarkers 
There was the expected significant reduction in urate in the cohort treated with 
allopurinol. TBARS a marker of oxidative stress was also significantly increased in the 
allopurinol arm but there was no significant change in other biomarkers (Table 15).Sub-
group analysis according the tertile of baseline urate (Table 11) and TBARS (Table 12) 
demonstrated no statistical difference between the lowest and highest tertile. 
 
 
Table 15 - Effect of Allopurinol on Biomarkers 
Variable 
 
Placebo Allopurinol p Value 
Urate (umol/L) -1.33 ± 37.04 -189.56 ± 91.95 <0.0001 
HsCRP (mg/L) -0.55 ± 2.10 0.22 ± 1.71 0.122 
TBARS (uM) -0.34 ± 0.83 0.26 ± 0.85 0.007 
NTProBNP (pg/mL) 109.08 ± 491.03 -109.03 ± 612.84 0.131 
PICP ng/L -0.18 ± 0.60 -0.05 ± 0.43 0.322 
Soluble ST2 ng/mL -1.02 ± 3.39 -0.61 ± 8.63 0.573 
 
 
3.9 Gadolinium Enhancement 
Thirteen subjects had late gadolinium enhancement at baseline, all except one were 
assigned to placebo, therefore analysis of the change in LGE between arms of the 




3.10 Study Drug Compliance 
This was assessed by counting the medications returned at each visit during the trial. 
There was no significant difference in medication compliance between those taking 
allopurinol and placebo. There was a significant reduction in urate in the allopurinol 
group compared to placebo (Table 15), with an order of magnitude of a 51.4% reduction 
in urate levels from baseline consistent with good compliance with allopurinol. The 
average daily dose of allopurinol in the intervention group was 547mg.  
 
Table 16 - Recorded Compliance 
 
 
Placebo Allopurinol p 
Compliance (%) 95.5 ± 4.5 94.9 ± 5.3 0.627 
 
 
3.11 Changes to Antihypertensive Medications 
Changes to all anti-hypertensive medications is demonstrated in Table 17. Although 
there are more alterations to antihypertensives in the allopurinol cohort this wasn’t 
detected as a significant change in BP control over 12months. Table 18 displays changes 
to RAS inhibitors during the trial as these can affect LVM independently of BP. There is 
a small number of changes in these medications during the study and therefore 






Table 17 - Changes in Antihypertensives 
 Placebo Allopurinol 
New/ Up titration of 
antihypertensive 
7 9 





Table 18 - Changes in RAS inhibiting medications 
 Placebo Allopurinol 
New/ Up titration of RAS 
inhibitor 
1 2 






3.12 Adverse Events 
Three serious adverse events occurred during the study that required hospitalisation 
however they were unrelated to the study medications (iatrogenic colonic perforation, 
infected dog bite requiring debridement, and arthralgia after a fall).  
In total there were 166 adverse events, 70 in the placebo group and 82 in the 
allopurinol arm. Table 19 displays the likely causality to the IMP for each arm of the 
study based on the summary of product characteristics. Of the three subjects who 
withdrew due to side effects in the allopurinol arm, two developed nausea and one 
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had a rash. Table 20 illustrates adverse events by system organ class as per the medical 
dictionary for regulatory activities (MedDRA) coding. There were two groups with 
clearly more events in the allopurinol cohort (gastrointestinal disorders and skin and 
subcutaneous tissue disorders) consistent with the two most common side effects (i.e. 
rash, nausea and vomiting). 
 
Table 19 - Adverse Event Causality to Study Medication 
Causality Placebo Allopurinol 
None 28 25 
Possible 40 49 
Probable 2 3 




















Table 20 - Adverse Event by System Organ Class 
System Organ Class Placebo Allopurinol 
General disorders and administration site conditions 6 6 
Infections and Infestations 6 6 
Nervous system disorders 10 12 
Surgical and medical procedures 2 0 
Blood and lymphatic system disorders 0 2 
Cardiac Disorders 2 4 
Ear and labyrinth disorders 1 0 
Eye disorders 0 1 
Gastrointestinal disorders 12 17 
Injury, poisoning and procedural complications 2 1 
Investigations 1 0 
Metabolism and nutrition disorders 1 2 
Musculoskeletal and connective tissue disorders 10 12 
Neoplasms benign, malignant and unspecified  1 0 
Psychiatric disorders 2 3 
Renal and urinary disorders 3 2 
Reproductive system and breast disorders 1 0 
Respiratory, thoracic and mediastinal disorders 2 2 
Skin and subcutaneous tissue disorders 5 10 







4.1 Main Findings 
The main finding of this study is that treatment with high dose allopurinol attenuated 
LVM regression compared to placebo, in an optimally treated hypertensive cohort, 
over a twelve-month period. There were no significant changes in other LV, LA 
volumes or ejection fraction measured by cardiac MRI, nor on measures of 
haemodynamics (blood pressure, FMD, augmentation index or pulse wave velocity). 
We found a significant rise in a marker of oxidative stress (TBARS) in the allopurinol 
arm compared to placebo, but no other significant difference in any other biomarker 
was detected.  
 
4.2 Possible Mechanisms to Explain Findings 
4.2.1 Oxidative Stress 
Uric acid (UA) is a major antioxidant in human plasma and an important intracellular 
free radical scavenger [256]. Previously discussed in chapter 1.3, uric acid can 
paradoxically become a pro-oxidant in certain conditions i.e. supra normal levels or 
when other anti-oxidants are depleted [256, 257]. This so called “urate redox shuttle” 
[26] is a plausible explanation for the unexpected findings in this trial that conflict with 
previous studies.  
Allopurinol has been found to regress left ventricular mass and improve both 
endothelial function and vascular stiffness in diseases across the cardiovascular 
spectrum (chronic kidney disease, ischaemic heart disease, diabetes mellitus) [40, 41, 
53]. These diseases are associated with high levels of oxidative stress [258] and 
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therefore lowering both xanthine oxidase generated ROS, and “pro-oxidant” uric acid 
with allopurinol could shift the redox balance favourably. Although hypertension is 
associated with increased levels of OS [259], this cohort had well-controlled BP at 
baseline, had normal or only mildly elevated levels of uric acid (360umol/L) and 
therefore the baseline levels of XO activity and OS were low. For comparison the uric 
acid levels in the studies discussed above ranged from 420 - 600µmol/L, but all had a 
similar baseline indexed MRI LVMI (60 – 71g/m2) compared to this trial (65g/m2) [40, 
53, 59]. The most likely explanation for the findings from this study is that allopurinol 
has effectively lowered “antioxidant” uric acid, thereby increasing oxidative stress and 
attenuating the LV mass regression.  An unfavourable change in the redox balance is 
supported by the significant increase in the marker of OS (TBARS) in the cohort taking 
allopurinol.  There was no clear pattern from sub-group analysis looking at tertile of 
baseline LVM, TBARS and urate to suggest an effect with higher/lower levels of these. 
Even in the upper tertile the mean urate is only mildly elevated (placebo 461umol/L, 
allopurinol 478umol/L).  
A sub-group analysis of the OPT-CHF trial found that patients with the highest levels of 
serum uric acid (>565µmol/L) benefited from oxypurinol, but there was a trend to 
harm in those with lower levels [260]. Another trial, the CARES study found a 
significantly higher all-cause and cardiovascular mortality in patients with gout and 
cardiovascular disease treated with febuxostat compared to allopurinol [69]. 
Febuxostat is a more potent XO inhibitor and had a greater effect on the serum urate 
than allopurinol, therefore a possible explanation may be a paradoxical increase in OS 
from urate lowering. J or U-shaped curves have been described regarding all-cause and 
cardiovascular mortality in both hypertensive and large general populations associated 
132 
 
with serum UA levels[23-25]. The threshold for uric acid where risk increases varies 
between studies but the mean final uric acid in this study was 204 ± 68 umol/L in 
males and 108 ± 33 umol/L in females, lower than any of the gender specific 
thresholds from the studies above.  
Although treatment with allopurinol itself may have a direct adverse effect, 
independent of uric acid, however this seems implausible and without a mechanistic 
explanation. Apoptosis is known to be stimulated by high levels of OS [73] therefore it 
is possible that LVM regression in the previous studies could be explained [40, 41, 53]. 
This is unlikely in the IHD and CKD cohorts as an improvement in endothelial function 
and vascular stiffness was demonstrated in both supporting a lowering of OS, but this 
was not shown in the trial with diabetes.  
 The PREVENT study demonstrated that serum levels of TBARs have been shown to be 
strongly, and independently predictive of cardiovascular events in patients with stable 
coronary disease [252]. Hence both the failure to regress LVM, lowering urate and 
increasing TBARS may in fact increase cardiovascular risk in this population. 
 
4.2.2 Blood Pressure and Antihypertensive Medications 
We studied subjects with treated, well controlled blood pressure, taking evidence-
based mediations that included a high percentage of ACE-I and ARBs. Although there 
are subtle differences in antihypertensive medications between arms no significant 
differences were found, and overall the number of medications in each arm are 
similar. No significant differences in blood pressure were found at baseline, nor any 
significant change over the trial period to explain the results. In fact, the baseline 
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systolic BP was higher and there was a slight increase in systolic BP in the placebo arm 
during the trial. Therefore, it is implausible that the results are caused by changes in BP 
during the study. It would be expected that any changes in antihypertensive 
medications during the trial would directly influence BP, however RAS inhibiting 
medication can reduce LVM independent of blood pressure [238]. There were a small 
number of changes to these medications during the study Table 18 and an analysis 
excluding these patients had no effect on the findings.  
The “placebo” effect on LVM may be due to the regression that has been 
demonstrated to occur for up to two years with well controlled hypertension [232, 
236]. Rekhraj et al noted a similar reduction in LVM within the placebo arm (-1.3± 4.5g) 
in their study [59]. It is possible that subtle beneficial lifestyle changes were made 
during the trial by the subjects and these contributed to the result.  A major strength 
of this the study was the blinding of both participants and investigators to study 
allocation both during the trial and data analysis reducing the risk of bias influencing 
the results.  
 
4.2.3 Weight 
Body mass index (BMI) has been shown to have an independent risk factor for left 
ventricular hypertrophy [175], and the work by MacMahon et al. demonstrated that a 
change in weight can have an influence on left ventricular mass independent of blood 
pressure [242]. At baseline there was no significant difference in the BMI and the 
weight change overall was greater in the placebo arm than allopurinol but was not 
found to be statistically significant (placebo -1.61 ± 4.79kg versus allopurinol -0.72 
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±3.05kg; p = 0.386). It is therefore unlikely that BMI or changes in weight had an 
influence on the primary finding in this trial.  
 
4.2.4 Endothelial Function and Vascular Stiffness 
Allopurinol has been found to improve vascular stiffness and endothelial function in a 
variety of conditions by reducing vascular oxidative stress [39, 41, 53]. This has been 
demonstrated by reducing XO generated ROS rather than lowering uric acid in subjects 
with heart failure [39]. Reduction in cardiac afterload by improvements in vascular 
function is proposed as one mechanism to explain reductions of LVM seen in previous 
studies [41, 53]. There were no significant differences in measures of endothelial 
function nor vascular stiffness at baseline or after twelve months between the groups 
to suggest an influence of these factors on the LV in this trial. In low vascular oxidative 
stress, allopurinol may have adversely impacted urate levels and any improvement 










5 STUDY LIMITATIONS 
This was a randomised controlled trial in a single centre with a small sample size and 
although not captured in the baseline demographics, a completely white population. 
Hypertension has a wide spectrum of severity, this cohort is on the less severe end of 
the spectrum and therefore does not represent the disease as a whole.Despite the 10 
subjects who withdrew from the study it was adequately powered for the primary end-
point. It is possible that there are subtle differences in the baseline demographics 
between the groups that influenced the results. This study has demonstrated the 
opposite effect on LVM than previous trials in different cohorts and therefore it is 
possible the results have occurred by chance.  
Although subjects fulfilled criteria for echocardiographic LVH, mean baseline CMRI 
LVM did not meet criteria for LVH. Screening for LVH using cardiac MRI would be 
impracticable and prohibitively expensive, echocardiography is an established method 
to diagnose LVH in clinical practice and was the method used previously in similar 
studies at our unit. The method for LV contouring excluded partial volume (i.e. <50 full 
thickness of the myocardium) areas at the basal LV, and the papillary muscles to 
improve repeatability and hence sensitivity to detect a change but may underestimate 
overall LV mass as a result. The basal slice has a large cross-sectional area and 
therefore can have considerable effect on the overall LVM, and the papillary muscles 
can account for up to 8.9% of the total LVM[261, 262]. Changes in LVM in this study 
are small and although statistically significant it is unclear whether they are clinically 
important. 
The LIFE study found that while most LVM regression occurs within the first year it can 
occur for up to two years [237]. Although subjects were enrolled if they had been on 
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stable anti-hypertensive medications for at least three months, it is possible changes 
to treatment outside this time frame could already have exerted an effect on LVM.  
Nineteen percent of subjects had a home blood pressure monitoring rather than 24-
hour ambulatory. Mean 24-hour systolic BP correlates best with LVM [178], it is 
possible that there are differences between arms of the trial in BP not detected in 
those who had home BP monitoring i.e. nocturnal hypertension.  
There are multiple factors however that influence measurements of endothelial 
function and vascular stiffness such as temperature, time of day, medications, food 
and smoking [160, 249]. Although we aimed to control factors that affect 
measurement of vascular stiffness and endothelial function, patients may have eaten, 
and or smoked prior to testing. Furthermore, it wasn’t always practical to repeat the 
scan at the same time of day because of availability of the patient/equipment or the 
timing of the MRI scan. It is also recommended that vasoactive medications are 
withheld before FMD, however this trial was testing the change due to allopurinol 
versus placebo, so we advised patients to take their usual medication before the tests.  
Although LVM regression using antihypertensives has established prognostic benefit 
(chapter 1.9.5), previous studies including this one has used LVM changes as a 







6 FUTURE RESEARCH 
Large randomised controlled trials to assess hard cardiovascular outcomes with the 
use of allopurinol are required. One such study the ALL-HEART trial currently in the 
follow-up phase, is testing allopurinol versus placebo in patients with ischaemic heart 
disease on the composite end-point of non-fatal MI, non-fatal CVA or CV death[263]. 
Sub-group analysis of this study specifically looking at baseline UA and outcomes could 
assess whether there the effect is universal in the population.  
It would be unethical to design a trial to assess whether allopurinol increased 
cardiovascular risk, future studies should select populations with the highest XO 
activity, oxidative stress or uric acid i.e. resistant hypertension or those with 
decompensated hypertensive heart disease.  
MRI has the advantage of tissue characterisation, the typical pattern of fibrosis in HHD 
is diffuse reactive rather than focal replacement. Therefore, T1 mapping could be used 
to quantify changes in the cellular and extracellular compartments over time and 
provide information on whether changes are occurring to the myocyte, extra-cellular 
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